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ABSTRACT




Medical imaging technology has allowed for unparalleled insight into the structure and function of
the human brain, giving clinicians powerful new tools for disease diagnosis and monitoring. Yet the
complex and high-dimensional nature of imaging data makes computational analysis challenging.
In multiple sclerosis (MS), this complexity is typically simplified by identifying regions of visible tissue
damage and measuring spatial extent. However, many common radiological measures have been
shown to be only weakly associated with clinical outcomes (a discovery that has been referred to
as “the clinico-radiological paradox”). We attempt to bridge this gap by developing statistical meth-
ods capable of extracting clinically relevant information from MRI scans in MS. Here, we discuss
three such techniques: a texture modeling approach to improve research on lesion dynamics; a
biomarker detection algorithm to support diagnostic decision-making; and a flexible multi-modal
group differences test to facilitate exploration of subtle disease processes. The performance of
these methods is illustrated using simulated and real data, and the opportunities and obstacles for
their clinical use are discussed.
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Multiple sclerosis (MS) is a chronic disease of the central nervous system, characterized by pro-
gressive cognitive and motor disability. Though treatments exist to reduce inflammatory activity and
slow clinical progression, there is currently no cure. The lack of a cure and the immense expense
of disease modifying therapies make MS a personally and societally devastating disease. Cur-
rently over two million people worldwide have an MS diagnosis (Wallin et al., 2019), and the costs
attributed to the disease are estimated to be roughly C14 billion per year in Europe (Gustavsson
et al., 2011) and $9 billion per year in the United States (Chen, Chonghasawat, and Leadholm,
2017). The high financial burden of MS treatments, and their heterogeneity in efficacy across pa-
tients, makes the detection of clinical biomarkers a vital goal in MS research. The presence of
robust biomarkers could facilitate better individualization of care, allow for more efficient clinical
trials, and even provide predictive insight into patients’ likely disease courses. Because MS is
characterized by demyelinating lesions that occur in the central nervous system, brain imaging has
taken a central role in the search for useful clinical markers. Magnetic resonance imaging (MRI)
is most commonly used to observe these lesions, especially in the white matter of the brain (Radu
and Sahraian, 2008). The presence of new lesions on MRI is often considered an important clinical
marker of disease activity, yet interesingly, MRI-based measures of disease severity have been elu-
sive. This lack of strong links between clinical outcomes and imaging measures has been dubbed
the ”clinico-radiological paradox” in MS (Barkhof, 2002).
Four primary reasons for this paradox have been proposed. (A) Issues with the clinical severity
measure. Part of the paradox may be related to the expanded disability status scale (EDSS), the
most commonly used measure of disease severity in MS research. EDSS is known to be a subjec-
tive and variable measure of severity. It is also ordinal and is subject to large temporal fluctuations,
characteristics that can complicate principled quantitative analysis of progression. (B) Lack of spinal
cord consideration. Though high-quality brain imaging has become relatively common in both clini-
cal and research centers in recent years, high-quality spinal cord imaging remains rare and difficult
to obtain. In terms of research, this has meant that scholars do not typically work with spinal cord
imaging data, forgoing formal analysis of spinal cord lesions that are likely to be more clinically in-
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formative than brain lesions. (C) Imprecise measures of lesion damage. Though brain imaging has
greatly improved in quality and spatial resolution, computationally obtaining fine-grained measures
of lesional damage remains difficult. Thus, many commonly used lesion measures are overly broad
and obscure relevant information at lower scales. (D) Neglect of normal-appearing brain tissue.
Because lesions are highly visible on brain imaging, much of the clinical and research focus is on
these regions of focal damage. However, it is known that even tissue that appears normal on brain
MRI is characterized by diffuse micro-scale damage that may contain additional clinical information.
Though explanations A and B are of considerable interest, we leave the improvement of the EDSS
to clinicians and measurement experts, and the improvement of spinal cord imaging to MR physi-
cists. Instead, in this work we have focused on probing the potential utility of statistical methodology
for mitigating the limitations posed by explanations C and D. In Chapters 2 and 3, we seek ways
to improve on the existing imprecise measures of lesion damage. In Chapter 2, we approach the
question of how to draw obscured anatomical information from commonly obtained lesion segmen-
tations. Specifically, we attempt to address the issue that accurately estimating the number of
lesions in a patient’s brain is highly difficult when patients have confluent (i.e., spatially overlap-
ping) lesions. To this end, we introduce a statistical technique for cross-sectionally counting and
clustering anatomically distinct lesions. We assess the validity, reliability, and clinical utility of our
procedure relative to other common lesion measures.
In Chapter 3 we investigate the diagnostic drawbacks of existing lesional assessment. Though
white-matter lesions are highly important to MS diagnosis and clinical characterization, their pres-
ence is not specific to MS. Indeed, the presence of white-matter lesions in other neurological disor-
ders has lead to many cases of misdiagnosis (Solomon, Klein, and Bourdette, 2012). The central
vein sign (CVS) is a promising MR imaging diagnostic biomarker for multiple sclerosis, yet the clin-
ical application of CVS as a biomarker is limited by interrater differences in its adjudication and the
immense time burden required for its assessment in each lesion in a patient’s MRI scan. Here, we
present an automated technique for the detection of the central vein sign in white matter lesions.
Using multi-modal MRI data, the proposed method derives a CVS probability for each lesion, as
well as a patient-level CVS biomarker. We assess the performance of proposed algorithm on a
sample of patients with white-matter lesions, some of whom have MS and some who have MS
“mimics.”
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In Chapter 4, we turn to the difficulty of detecting disease processes in normal-appearing brain
tissue. In simple cases, these processes can be quantified using summary statistics of voxel inten-
sities. However, the manifestation of a disease process in imaging data is often unknown, or ap-
pears as a complex and nonlinear relationship between the voxel intensities on various modalities.
When the relevant pattern is unknown, summary statistics are often unable to capture differences
between disease groups, and their use may encourage post hoc searches for the optimal summary
measure. Here, we introduce the multi-modal density testing (MMDT) framework for the naive dis-
covery of group differences in voxel intensity profiles. MMDT operationalizes multi-modal magnetic
resonance imaging (MRI) data as multivariate subject-level densities of voxel intensities and utilizes
kernel density estimation to develop a local two-sample test for individual points within the density
space. We perform a detailed simulation study to assess the performance of MMDT. We also apply
MMDT to a sample of subjects with MS and subjects with MS mimics to determine whether there
are subtle differences in normal-appearing thalamic tissue.
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CHAPTER 2
MATHEMATICAL AND STATISTICAL SEPARATION OF SPATIALLY CONFLUENT
WHITE-MATTER LESIONS
2.1. Introduction
Multiple sclerosis is a neuroinflammatory disorder characterized by demyelinating lesions that occur
in the central nervous system. MRI is the most commonly used method to observe these lesions,
especially in the white matter of the brain (Radu and Sahraian, 2008). The presence of new lesions
on MRI is often considered an important clinical marker of disease activity, yet MRI-based measures
of disease severity have been elusive (Barkhof, 2002). The total lesion burden in the white matter,
or “lesion load” – measured as volume or volume fraction of brain size – is often used in the study
of MS, typically as a measure of disease severity (Popescu et al., 2013) and as a clinical trial
outcome (Calabresi et al., 2014). However, lesion load has consistently shown a surprisingly weak
association with clinical measures of disease severity, calling into question its usefulness as a
surrogate and reinforcing the need for further development of MRI outcomes for MS (Barkhof, 2002;
Thompson et al., 1990).
In past years, several clinical studies have discussed the number of lesions in a patient’s brain as
a possible outcome of interest (Brex et al., 2002; Khoury et al., 1994; Rudick et al., 2006). In
these studies, baseline lesion count has been shown to be correlated with the expanded disability
status scale (EDSS) and changes in lesion count have been shown to be correlated with changes
in EDSS. However, obtaining an accurate count of anatomically distinct lesions in the brain can be
costly and logistically challenging, typically requiring expert review or automated analysis of scans
taken at frequent follow-up visits. This process is especially difficult in patients with a high lesion
load and many confluent lesions (Zivadinov et al., 2008).
Confluent lesions commonly occur when anatomically distinct lesions (i.e., lesions that arise due
to spatially separate sources of structural damage in the brain, usually separated in time) occur in
close proximity to each other, creating a larger connected region of lesion tissue. Depending on
the level of lesion burden, confluent lesions can range from two overlapping lesions with a single
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connecting edge to dozens of connected lesions spanning large stretches of white matter. The
existence of such confluent tissue can make it difficult or impossible to estimate the number distinct
lesions in the brain at any given visit. To obtain accurate lesion counts a patient must be scanned
regularly, with temporality of appearance serving to separate spatially confluent lesions. However,
MRI scans are extremely costly, which can make regular follow-up visits infeasible. Additionally,
in patients with a great deal of disease activity, even monthly or bi-monthly scans can produce
multiple new lesions that are overlapping in space (Guttmann et al., 2016; Harris et al., 1991).
These considerations render lesion counts unavailable or inaccurate in most clinical settings, in
which patients are typically scanned yearly or twice yearly.
To address this issue, the current study introduces a statistical analysis technique for obtaining
valid and reliable estimates of lesion count from a single cross-sectional MRI study. This fully
automated method utilizes cutting-edge statistical models for segmenting lesion tissue and well-
demonstrated mathematical methods for quantifying texture to obtain the number and location of
temporally distinct white matter lesions. Additionally, this study provides evidence that lesion counts
are associated with clinical measures of disease severity, independent of total lesion volume.
2.2. Proposed lesion count algorithm
To obtain the lesion count estimate in a given subject, the following steps are carried out. First, a
map of lesion probability at each voxel in the brain is obtained using preprocessed and co-registered
MRI volumes from a single visit. Depending on the automated segmentation method that is used,
some combination of T1-weighted (T1), fluid attenuated inversion recovery (FLAIR), T2-weighted
(T2), and proton density (PD) volumes may be required for probability estimation. A threshold is
then applied to the probability map to create a binary mask of regions that are considered lesion
tissue.
Using the probability map, the texture of the lesion tissue is quantified to find regions that exhibit the
properties that would be expected of the center of a single lesion. Local texture of the 3-dimensional
probability map is quantified via the Taylor expansion in the neighborhood of a given location, x0,
I(x0 + x) ⇡ I(x0) + xTrI(x0) + xTH(x0) (x), (2.1)
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@a@b . In this context, the Hessian matrix describes the second-order variation in image
intensity in the local neighborhood around a specific location. Because lesion probability maps
are obtained on a discrete grid, as opposed to a smooth differentiable function, we estimate the
Hessian matrix at each voxel by performing convolution of the image with discretized derivative of
Gaussian kernels. Specifically,







where G(x0, s) = (2⇡s2) 3/2exp( xT0 x0/2s2) is a 3-dimensional Gaussian with scale s, and ⇤ rep-
resents convolution. Using the estimated Hessian matrices across the lesion probability map, we
seek to obtain a measure of the local concavity or convexity of the texture. To do so, we calculate
the eigenvalues of the Hessian matrix at each voxel, which represent the three primary directions of
change in lesion probability at that voxel. Specifically, for a 3D image, each location will yield three
eigenvalues,  1,  2, and  3. If  1 < 0,  2 < 0, and  3 < 0, the surface is locally concave down. If
any  i > 0, the surface is inconsistent (e.g., it may resemble a 3D saddle point).
Because we expect the centers of lesions to be characterized by local peaks in the probability
map, we consider center voxels to be those for which all three eigenvalues are negative. This
follows from the commonly accepted pathology of MS lesions, in which initial damage to a vein
causes residual inflammation to spread outwards from the vein in a relatively ovoid fashion, with
less damage occurring around the periphery of the visible lesion (Gaitan et al., 2011). Therefore,
voxels are eliminated if any of the three eigenvalues are positive, indicating that the voxel is less
likely to be lesion than its surroundings in at least one direction. Remaining voxels with three
negative eigenvalues are clustered by location, and connected clusters (operationalized as the
centers of distinct lesions) are counted. Figure 2.1 provides a visual example of this technique.
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Figure 2.1: Visualization of the performance of the proposed count. (A) Example probability map
(left), and maps of the three Hessian eigenvalues used to quantify lesion texture and find distinct
lesion centers. Red represents negative eigenvalue regions, in which lesion probability is a local
maximum along a given direction, and blue represents positive eigenvalue regions, in which lesion
probability is a local minimum along a given direction. (B) Example of a region with confluent
lesion tissue. Connected components (middle) finds one confluent lesion in the highlighted region.
Proposed method (right) finds six distinct lesion centers in the highlighted region on the visualized
axial slice.
2.3. Validity, reliability, and clinical utility in real data
2.3.1. Data and preprocessing
Validation and clinico-radiological association data. Sixty subjects diagnosed with MS were
scanned between 2000 and 2008 on a monthly basis over a period of up to 5.5 years (mean = 2.2
years, sd = 1.2) as part of a natural history study at the National Institute of Neurological Disorders
and Stroke in Bethesda, Maryland. The subjects ranged from 18 to 60 years of age, with a mean
age of 38 years (sd = 9). Of the 60 subjects, 38 were female and 22 were male. The majority of the
subjects (n = 44) were diagnosed with relapsing-remitting MS, 13 were characterized as secondary-
progressive, one as primary progressive, and two were unspecified. Subjects were either untreated
or treated with a variety of disease-modifying therapies during the observation period, including
both FDA-approved (various preparations of interferon-beta) and experimental therapies.
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Details of the image acquisition and preprocessing have been previously published (Sweeney et
al., 2016) and are briefly summarized in this section. Whole-brain 2D FLAIR, PD, T2, and 3D T1-
weighted volumes were acquired in a 1.5 tesla (T) MRI scanner (Signa Excite HDxt; GE Healthcare,
Milwaukee, Wisconsin). The 2D FLAIR, PD, and T2 volumes were acquired using fast-spin-echo
sequences, and the 3D T1 volume was acquired using a gradient-echo sequence. All scanning
parameters were clinically optimized for each acquired image. Subjects were each scanned over
multiple visits, and subjects’ images at each visit were rigidly co-registered longitudinally and across
sequences to a template space (Fonov et al., 2011).
All images were N4 bias-corrected, and FLAIR, T2, and PD volumes for each subject were inter-
polated and rigidly co-registered to the T1 volume in isotropic 1 mm3 space (Avants et al., 2009).
Extracerebral voxels were removed using the T1 volume via a skull-stripping procedure (Carass et
al., 2007), and intensity normalization (Shinohara et al., 2014) of the volumes based on z-scoring
was applied. Studies were manually quality controlled by a researcher with over five years’ experi-
ence with structural MRI, and studies with analysis-limiting motion or other artifacts were removed.
Following preprocessing and quality control, automatic lesion segmentation was performed on co-
registered T1, T2, FLAIR, and PD volumes using the OASIS is Automated Statistical Inference for
Segmentation (OASIS) model (Sweeney et al., 2013b) to produce a lesion probability map for each
subject. A conservative threshold of 0.30 was applied to the probability maps to create binary lesion
masks.
Reliability data. To test reliability, also referred to as repeatability, data were analyzed from a 45-
year-old man diagnosed with clinically stable relapsing-remitting MS. This patient was imaged at
seven sites in the United States as part of a pilot study for the North American Imaging in Multiple
Sclerosis (NAIMS) Cooperative. He was characterized as having mild-to-moderate physical disabil-
ity, which was stable between the first and last visits, and had no clinical relapses nor radiological
changes during the course of the study (Shinohara et al., 2017).
Details of the image acquisition have been previously published (Shinohara et al., 2017) and are
briefly summarized in this section. Whole-brain 3D high-resolution FLAIR, T2, and T1-weighted
volumes were acquired on seven 3T Siemens MRI scanners across the United States (4 Skyra,
2 Tim Trio, 1 Verio). A standardized high-resolution scanning protocol was developed through a
consensus agreement in the NAIMS Cooperative, and was used to the extent possible (allowing for
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different scanner types and software versions) for each scan. The participant was scanned twice
on the same day at each site, and was removed and repositioned between scan and rescan.
All images were N4 bias-corrected, and the subject’s images at each scan were rigidly co-registered
across sequences to the T1 volume in isotropic 1 mm3 space (Avants et al., 2009). Extracerebral
voxels were removed using the T1 volume via a skull-stripping procedure (Jenkinson, Pechaud,
and Smith, 2005), and intensity normalization (Shinohara et al., 2014) of the volumes based on
z-scoring was applied. Following preprocessing, automatic lesion segmentation was performed on
co-registered T1, T2, and FLAIR volumes using an extension of the OASIS model (Valcarcel et al.,
2017) to produce a lesion probability map for each scan session. A conservative threshold of 0.30
was applied to the probability maps to create binary lesion masks.
2.3.2. Statistical analysis
Validation. Using the longitudinal nature of the data, a ‘gold-standard’ count of lesions that ap-
peared during the course of the study was developed for validation. A state-of-the-art technique
for segmenting new lesions since a previous visit (Sweeney et al., 2013a) was applied at each visit
after baseline, resulting in the number and location of new lesions at each visit for every patient.
For the gold-standard count, segmented regions containing lesions that were separated in space
or time were considered distinct. For example, if a large contiguous region at study’s end consisted
of one lesion that appeared at the sixth visit and one lesion that appeared at the eighth visit, this
would be considered two lesions in the gold-standard count.
The gold-standard count, henceforth referred to as CG, was compared to two counts obtained
cross-sectionally at the final of observation for each patient. The first, CP , is the count based on
the technique proposed in this study. CP was obtained by applying the algorithm described in
Section 2.1 to the images obtained at each patient’s final visit, then restricting the count to the
number of lesion centers contained in the lesion voxels determined to have appeared during the
course of the study. Importantly, this restriction means that CP represents a subset of the total
number of lesions in a subject’s scan, and is distinct from the full lesion count that is later described
in the context of the clinico-radiological analysis. This limitation was implemented to make direct
comparison between CP and CG possible, since a gold-standard count can only be obtained for
lesions that appeared during the study.
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Figure 2.2: Example of the lesion counts in a region with four apparently distinct lesions, two
of which develop with observable temporal separation. (A) Temporal development of two new and
temporally distinct lesions over the course of roughly three months. (B) Performance of a connected
components count and the proposed count, respectively, at the example subject’s final scan. The
connected components method finds one confluent lesion in the visualized space (connected in an
adjacent plane), and the proposed method finds four distinct lesion centers.
The second cross-sectional count, CC , refers to a count based on the standard connected compo-
nents technique. CC was obtained by performing lesion segmentation on the images obtained at
each patient’s final visit, thresholding at a probability of 0.30, and labeling lesions as distinct if they
were separated in space. CC was then restricted to the number of unique lesion labels contained in
the lesion voxels known to have appeared during the course of the study, in order to facilitate com-
parison with CP and CG. An example of this longitudinal procedure, and the resulting estimated
counts, can be seen in Figure 2.2.
Comparison between CG, CC , and CP occurred in two ways. First, to assess the linear correspon-
dence between the gold-standard and the different counting techniques, the CG-CP and CG-CC
correlations were compared. Then, to determine whether the counts themselves differ meaning-
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fully from the gold-standard, paired t-tests were run for CG and CP , as well as CG and CC .
Reliability. Determination of the reliability of the proposed counting method was based on the
coefficient of variation (CV) of the counts obtained from the 14 repeated scans. Because the typical
connected components technique for counting automatically or manually segmented lesions yields
a stable but invalid estimate of the true count, there is no current gold-standard CV for a lesion
count. Thus, the CV of the proposed count was compared to a commonly used outcome measure
for MS: total cerebral lesion volume (“lesion load”).
This comparison took place in two contexts. The first represented a fully automated version of
the proposed count, in which variation may arise from false negatives in the segmentation mask,
false positives in the segmentation mask, thresholding of the segmentation mask, and changes
in the Hessian structure of the segmentation mask. This coefficient was compared to the CV of
automated lesion load, as determined by the segmentation method.
The second context represented a manually supplemented version of the count, where a mask of
lesion tissue was provided by an expert rater (Shinohara et al., 2017), and the count was obtained
using the segmentation probability map within the manual lesion tissue mask. In this case, variation
in the count arises solely due to changes in the Hessian structure of the segmentation mask and
changes in the manual segmentation. This coefficient was compared to the CV of the manually
obtained lesion load.
Clinico-radiological association. As EDSS is known to be noisy, a more stable measure of neu-
rologic disability was created by averaging the EDSS scores over all visits for each subject in the
NINDS longitudinal study, hereby referred to as EDSSavg. One subject had no EDSS information
across all follow-ups, and was excluded from this analysis. Using OASIS lesion probability maps
(Sweeney et al., 2013b), lesion load was obtained at the final visit for each subject using a probabil-
ity threshold of 0.30. Then, using the lesion count technique described in Section 2.1, a full count of
white matter lesions at the final visit was obtained for each subject. Importantly, the counts obtained
for the clinico-radiological analysis are distinct from the CP measure described previously, as these
counts represent the application of the proposed method to the entire brain, while CP represents
the application of the proposed method to only lesion tissue that appeared during the course of the
longitudinal study.
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To determine the clinical relevance of the proposed lesion count independent of other potentially
confounding variables, a linear regression model was created for EDSSavg with age, lesion load,
and lesion count as predictors. The lesion count’s added statistical contribution was quantified
using a Wald test, which is inferentially identical to a likelihood ratio test in this context, and its
added clinical contribution was quantified by the increase in the model’s adjusted R2. Additionally,
Pearson correlations with EDSSavg were calculated for lesion load and lesion count, as well as a
new variable we refer to as average lesion size (defined as lesion load divided by lesion count).
2.3.3. Results
Validation. The temporally informed gold-standard count of new lesions appearing over the course
of study, CG, ranged from 0 to 75 among the 60 subjects, with a median of 4 (IQR = [1, 12]). The
connected components count, CC , ranged from 0 to 14 with a median of 2 (IQR = [1, 5]). The
proposed count, CP , ranged from 0 to 60 with a median of 5 (IQR = [1, 15]).
The correlation between CP and CG was 0.97, compared to the correlation of 0.67 between CC
and CG. Figure 2.3 shows the scatterplots for the two linear associations, along with the line
demonstrating a one-to-one relationship. The paired t-test comparing CC and CG yielded a highly
significant result (t59 = 4.19, p < 0.001), with CG being 6.9 lesions larger than CC on average (95%
CI: [3.6, 10.2]). The paired t-test comparing CP and CG did not detect a significant difference
between the counts (t59 =  0.83, p = 0.41), with CP being 0.4 lesions larger than CG on average
(95% CI: [-1.3, 0.5]).
Reliability. For the fully automated count, the coefficient of variation (CV) was 0.19, compared to
a CV of .22 for the automated lesion load. Using the manual segmentation as a mask, the CV for
the lesion count was reduced to 0.12, compared to a CV of 0.10 for the manual lesion load. In
one case, automated lesion segmentation was discovered to have failed, creating a probability map
with a drastically different Hessian structure and large regions of false positive segmentation. With
this scan removed the CV of the fully automated lesion count remained at 0.19 and the CV of the
manual segmentation-based lesion count dropped to less than 0.06, suggesting that the proposed
count has equivalent or lower variability than the current clinical standard of lesion load.
Clinico-radiological association. Accounting for lesion load and age, the proposed lesion count
was negatively associated with EDSSavg (t58 =  2.73, p < 0.01), suggesting that for a given lesion
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Figure 2.3: Scatterplot for the comparison between the gold-standard count, the connected com-
ponents count, and the proposed count. Diagonal line represents a one-to-one relationship, pur-
ple points represent the connected components count, and orange points represent the proposed
count.
load and age, a higher count is associated with lower disease severity. The inclusion of lesion count
in the model explains an additional 10% of the variance in EDSSavg compared to a model with only
age and lesion load, providing support to the hypothesis that the proposed count contains disease
information independent of other commonly used measures.
The Pearson correlation between lesion load and EDSSavg was small and did not reach significance
(r = 0.10, p = 0.44), nor did the correlation between lesion count and EDSSavg (r =  0.12, p =
0.36). However, average lesion size was significantly correlated with EDSSavg (r = 0.35, p < 0.01),
indicating that larger lesions were associated with higher disability.
2.4. Full lesion clustering via Gaussian mixture models
This method is able to provide an accurate and clinically relevant estimate of A) the number of
lesions, and B) the location of distinct lesion centers. However, many areas of research and clinical
practice in multiple sclerosis require knowledge of not only the location of distinct lesion centers, but
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also the location of their edges and the boundaries between them. To accomplish this, clustering
would need to be performed over all lesion voxels. Because MS lesions are known to arise from
isotropic inflammatory demyelination around a central vein (e.g., Fog, 1964; Tallantyre et al., 2011),
the degree of lesional damage across the brain could reasonably be thought to resemble a surface
constructed by a mixture of Gaussian-shaped lesion components. Thus, in this preliminary analysis
we seek to perform lesion voxel clustering via Gaussian mixture modeling (GMM) of the lesion
probability map.
2.4.1. Gaussian mixture model of sampled points
Though prior work has used Bayesian mixture models directly on probability-like maps (specifically,
on fMRI activation maps; Kim, Smyth, and Stern, 2010), that work relied on various ad-hoc ap-
proaches and did not appear to provide biologically plausible lesion clusters in MS data. Instead,
here we approach this problem by treating the lesion probability map, in which discrete voxels have
an associated “lesionness” score between 0 and 1, as a binned and scaled probability density
function. This framing allows us to then sample independent observations from that density in con-
tinuous space. These sampled observations, z = {z1, ..., zm}, can then be directly modeled as a










where zi is the three-dimensional location of the ith sampled point,  k is the mixing probability of
lesion k, µk is its mean/location vector, and ⌃k is its covariance/shape matrix.
The parameters of this model can be estimated using the expectation-maximization (EM) algorithm,
yielding a location and shape for each lesion component. With these estimates, probabilistic clus-
tering can then be performed back in the space of the lesion probability map using the location
of each voxel. Importantly, the number of lesion components, K, is not estimated, but is instead
assumed. Here, we propose utilizing the previously described lesion counting method to obtain
a preliminary estimate of K, K⇤, fitting the Gaussian mixture model over a range of possible val-
ues [0.8 ⇤K⇤, 1.2 ⇤K⇤], and selecting the best fitting model according to the Bayesian information
criterion (BIC).
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Figure 2.4: Design of lesion clustering simulation. Left-most box shows simulated lesion probability
map, with orange points showing mean location of Gaussian lesion components. (A) Steps of the
Hessian eigenvalue-based lesion clustering, in which centers are detected and nearest neighbors
clustering is performed on non-central voxels. (B) Steps of the GMM-based lesion clustering, in
which points are sampled from the lesion probability map, lesion locations and spreads are esti-
mated via a GMM, and probabilistic clustering is performed on discrete voxel locations.
2.4.2. Simulation study
To assess the performance of this clustering procedure, we designed a preliminary simulation study.
We simulated lesion probability maps by drawing K latent Gaussian “lesions” with random mean/lo-
cation vectors, covariance/spread matrices, and height/scale values. Discrete kernels from each
lesion component were placed onto a shared grid to induce confluence. Because the exact loca-
tion, shape, and scale of each lesion was set, the true clustering of voxels (i.e., which component
maximally contributed to the intensity at each voxel) was known a priori. To determine how the
degree of confluence affects the clustering performance, we varied K between 5 and 10. Addition-
ally, as the number of sampled points, m, needs to be pre-selected, we examined performance for
m = 2 ⇤ v, 4 ⇤ v, and 8 ⇤ v, where v is the number of voxels in the image. The proposed GMM-
based clustering method was compared to a nonparametric Hessian eigenvalue-based clustering
method; here, lesion centers were detected according to the procedure described previously, and
non-central voxels were assigned to the nearest center cluster (see Figure 2.4).
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Figure 2.5: Simulated erformance of lesion clustering methods (A) Left panel shows the average
estimated number of distinct lesions (y-axis) compared to the true number of simulated lesion (x-
axis) across methods. Right panel shows the proportion of simulations for which each method
estimated the correct number of lesions. (B) Left panel shows the clustering accuracy of each
method as a function of the number of lesions/degree of confluence. Accuracy is measured by the
proportion of voxels that were correctly clustered. Right panel shows the clustering accuracy for
cases in which all methods estimated the correct number of lesions.
The simulation gives preliminary evidence that the lesion counting method described previously has
a slight bias towards underestimation in cases of severe confluence (Figure 2.5A). This bias seems
to be mitigated by the GMM, but only when a large number of points are sampled (i.e., at least four
times as many points as voxels in the image). Though this may be computationally intractable for
large images, GMMs could potentially be fit to patches of locally confluent regions, as opposed to
fitting one model over the full image. This study also shows that GMMs with a large number of
sampled points tend to cluster voxels more accurately than the eigenvalue-based method (Figure
2.5B). However, the GMM-based method’s accuracy advantage appears to be largely due to its
increased likelihood of obtaining the correct count. Conditional on estimating the correct number
of lesions, all methods have similar clustering accuracy. Further analysis is needed to determine
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whether this is a meaningful equivalence or simply a ceiling effect.
2.5. Discussion
In this chapter, we introduce a novel technique for obtaining cross-sectional counts of anatomically
distinct lesions, and demonstrate it to be a valid, reliable, and clinically meaningful biomarker for MS
disease status. Utilizing information contained in the Hessian structure of lesion probability maps
produced by automated segmentation methods, this technique counts distinct lesions by identifying
regions that resemble the physiological traits of distinct lesion centers.
Validity of this measure was established by comparing counts obtained at a single time point to gold-
standard counts that incorporated temporal information on lesion development. The proposed count
had a correlation of 0.97 with the gold-standard count, indicating very strong validity of this measure.
A count obtained using the connected components method had only a 0.67 correlation with the
gold-standard, and appeared to strongly underestimate the number of lesions in individuals who
developed more than one or two lesions per year over the course of the study. This underestimation
manifested in a highly significant difference between the connected components counts and the
gold-standard counts in a paired t-test, whereas no difference was found between the proposed
counts and the gold-standard counts. These findings demonstrate that the proposed technique
yields a count that is consistent with the natural history of lesion formation.
Reliability was considered using a rich set of data from the NAIMS Cooperative. In that study, a
clinically and radiologically stable subject was scanned two times at each of seven different sites
across the United States. To judge the reliability of the proposed measure, the lesion count was
obtained for all 14 scans of this subject, and the coefficient of variation of the counts was compared
to that of lesion load in two contexts. In the fully automated comparison, lesion count had a slightly
lower CV than lesion load. This indicates that across repeated scans of the same brain, automated
lesion count is a less variable measure than automated lesion load. In the manually supplemented
comparison, lesion count had a slightly higher CV than lesion load, implying that lesion load is a
slightly less variable measure than lesion count when calculated using expert lesion segmentation
masks. Upon inspection there appeared to be one scan where automated lesion segmentation
failed, producing an abnormal Hessian structure within the manually segmented lesion mask. With
this scan removed, the CV of lesion count dropped to slightly more than half that of manual lesion
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load. This suggests that when automated lesion segmentation methods perform as expected,
lesion count is appreciably more reliable than even manual lesion load, a widely used measure of
disease severity.
Clinically, the lesion count measure appears to be a potentially important addition to commonly
used radiological biomarkers for MS. In a model accounting for lesion load and age, lesion count
was highly significantly associated with EDSS. Interestingly, this association was negative, indicat-
ing that for subjects who have similar lesion load, better outcomes are associated with more (and
smaller) lesions rather than fewer (and larger) lesions. This lends support to the idea that neither
the number of lesions nor the amount of tissue damage alone captures all relevant clinical infor-
mation, and instead suggests they should be considered together. One way to conceptualize the
combination of these metrics is average lesion size, which taps into the degree to which the brain
is capable of halting the growth of lesions and encouraging lesional recovery (Meier and Guttmann,
2003, 2006; Sweeney et al., 2016) after incidence.
To investigate this concept more directly, a measure of average lesion size was created by dividing
lesion load by lesion count. Pearson correlations with EDSS were then compared for the three
biomarkers of lesion load, lesion count, and average lesion size. These findings provided further
support for the combined importance of lesion load and lesion count, with both showing small and
nonsignificant associations with EDSS. However, average lesion size showed a significant positive
association with EDSS, consistent with the notion that the brain’s ability to slow or stop lesion
growth is clinically relevant. These findings point to the importance of considering lesion count in
MS research, and provide further evidence of the validity of the proposed counting technique.
A limitation of the current study is the possibility of alternate explanations of confluence that are not
accounted for in the design of the proposed count. It has been hypothesized that confluent lesions
may occasionally occur as a result of the growth of older lesions, or the expansion of pathological
processes. Future research should consider the degree to which this technique does or does not
characterize these types of confluence as anatomically distinct lesions. Additionally, the current
analyses do not account for the possibility of vascular comorbidity, which is a common and notable
occurence in MS patients. Future work should investigate the performance of this algorithm in the
presence of vascular lesions.
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The lesion count method presented in this chapter has several appealing features, including its
low computational burden and its easy and flexible implementation. Computationally, the counting
algorithm takes less than a minute to run once probability maps are obtained. The speed of the
full technique varies depending on the lesion segmentation method used, but took approximately
25 minutes per subject as presented in this study. In terms of implementation, this method can
be quickly and easily coded in any program capable of calculating the Hessian structure of a 3D
image, a feature included in most image processing packages. It can also be used with any le-
sion segmentation method that yields a probability map, allowing it to be implemented within most
pipelines regardless of preferred segmentation algorithm.
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CHAPTER 3
INTEGRATION OF MULTIPLE MRI MODALITIES FOR THE AUTOMATIC DETECTION OF
CENTRAL VEIN SIGN
3.1. Introduction
In recent decades, assessment of magnetic resonance imaging characteristics have factored heav-
ily in the diagnosis of MS, with much importance placed on the distribution (dissemination in space)
and time course of lesions (dissemination in time) (McDonald et al., 2001) in patients present-
ing with clinical symptoms typical for MS. However, current imaging-based diagnostic criteria favor
sensitivity over specificity, making misdiagnosis of MS relatively common (Solomon et al., 2016a;
Solomon, Klein, and Bourdette, 2012). This is especially true among disorders that demonstrate
white matter lesions similar to those found in MS (Aliaga and Barkhof, 2014; Miller et al., 2008).
Because inflammatory demyelination in the MS white matter is perivenular, the identification of a
vein traversing the center of a lesion has been proposed as a diagnostic tool capable of distinguish-
ing MS lesions from white matter abnormalities arising from other diseases (Fog, 1964; Tallantyre
et al., 2011). The potential for this marker to be used in the diagnosis of MS has been advanced by
recent developments in MRI pulse sequences, which have enabled detailed imaging of veins in the
brain (Campion et al., 2017; Reichenbach et al., 1997; Sati et al., 2012). Using these sequences,
researchers have provided strong evidence that higher proportions of MS lesions show central vein
sign (CVS) compared to lesions resulting from other disease processes commonly mistaken for
MS (Kilsdonk et al., 2014; Kister et al., 2013; Mistry et al., 2016; Sinnecker et al., 2012; Solomon
et al., 2016b; Tallantyre et al., 2011; Wuerfel et al., 2012). This finding has been demonstrated
for neuromyelitis optica spectrum disorder (NMOSD), systemic autoimmune diseases (SAD), cere-
bral small vessel disease (CSVD), Susac’s syndrome, and migraine. While further replication in
a prospective setting is still necessary, a high proportion of brain MRI lesions demonstrating CVS
appears to have potential as a biomarker with high specificity for MS.
Unfortunately, important barriers limit the feasibility of clinical application of CVS. Two such limita-
tions are the presence of intra- and inter-rater variability in the subjective assessment of CVS, and
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the time required to adjudicate CVS in every MRI lesion per patient. Recent studies have attempted
to mitigate the time burden associated with CVS assessment by limiting the number of lesions that
are examined (Mistry et al., 2016; Solomon et al., 2017b). However, these techniques have the
potential to increase variability, and have generally not been as successful as the evaluation of the
proportion of CVS in all MRI lesions per patient (Maggi et al., 2018; Tallantyre et al., 2011). Im-
portantly, in studies that adjudicate all lesions per patient, optimal proportion cutoffs have differed
across study sites and disease comparisons (Maggi et al., 2018; Mistry et al., 2016; Tallantyre et al.,
2011). This variability highlights the need for thorough comparison and optimization of these cutoffs
across samples and diseases, yet the same issues of rater subjectivity and temporal burden make
this type of research difficult. As such, the current study introduces an algorithm for the automatic
determination of CVS in white matter lesions, and presents a fully automated patient-level diagnos-
tic biomarker. In this chapter, we describe the CVS detection pipeline, present statistical measures
of judgment accuracy, and discuss the implications and next steps for this line of research.
3.2. Proposed CVS detection algorithm
To adjudicate CVS for each lesion in a given participant, several steps are carried out. We first
present the overall summary and then address each step, with associated rationale, in detail below.
To perform the algorithm, a T1-weighted volume (T1), T2-weighted FLAIR volume (T2-FLAIR), and
T2*-weighted segmented echo-planar imaging volume (T2*-EPI) are required. 1) A map of the veins
present in the T2*-EPI volume is created using a process referred to as vesselness filtering, and
the vein map is rigidly registered to the T1 volume. 2) White matter lesions are segmented using
the T1 and T2-FLAIR volumes. 3) Clear lesion boundaries are then determined using a process
that removes ambiguous boundary voxels. 4) Periventricular lesions are removed from candidacy,
per guidelines given by the North American Imaging in Multiple Sclerosis (NAIMS) cooperative (Sati
et al., 2016). 5) A permutation procedure is carried out to determine whether identified veins occur
in the center of a given lesion to a greater degree than would be expected by chance. This yields a
probability of CVS for each lesion j in patient i’s scan, denoted ⇡ij . Lesion-level CVS probabilities
are then averaged to obtain a patient-level CVS biomarker, denoted  i. 6) To account for errors in
automated lesion segmentation, the lesion probability map can be manually cleaned prior to central
vein detection, yielding a semi-automated biomarker,  si . Figure 3.1 demonstrates the algorithm’s
steps on an example lesion. Importantly, while figures are necessarily presented in 2D space, all
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methods undertaken for this procedure are conducted in 3D volumetric space, and simultaneously
consider all three planes of the image.
Figure 3.1: Visualization of the CVS detection algorithm. (A) Axial slice of T2*-EPI (left) and result-
ing Frangi vesselness map (right). (B) Axial slice of FLAIR volume and resulting lesion probability
map. (C) Example distance-to-boundary (centrality) measure for one lesion. (D) Example Frangi
vesselness for one lesion. (E) Centrality with vesselness overlay. Lesion-level CVS probability
following permutation was 0.99.
3.2.1. Vesselness filtering
Vein maps in the brain are created in order to later determine presence or absence of veins in each
lesion. To do this, the Frangi vesselness filter (Frangi et al., 1998) is applied to the unregistered
T2*-EPI volume (for the application to data, this study used the Convert3D toolbox), producing a
map of scores   0, with scores of 0 implying no vesselness qualities. The Frangi filter is a vessel
enhancement algorithm based on the Hessian matrix at each voxel, in which the second-order
structure of the image is obtained through convolution with derivatives of Gaussian kernels. The
scores are calculated using the eigenvalues of the Hessian matrix, specifically picking up on tubular
structures that are darker (or lighter, depending on the implementation) than their surroundings.
After being obtained in the unregistered T2*-EPI space, these “vesselness” maps are then rigidly
registered to the T1 space.
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3.2.2. Lesion segmentation
To determine the location and shape of white matter lesions, automatic lesion segmentation is
performed on co-registered T1 and T2-FLAIR volumes. For the application to data, this study used
the Method for Inter-Modal Segmentation Analysis (MIMoSA) model (Valcarcel et al., 2017) in the
R statistical environment (R: A Language and Environment for Statistical Computing 2015). The
lesion segmentation algorithm produces a map containing the probabilities that each voxel is part
of a lesion. For the results presented in this chapter, a threshold of 0.30 is applied to this probability
map in order to create a binary lesion mask. The threshold of 0.30 was chosen because previous
work has found it to be a conservative cutoff that can limit the amount of false positive lesion tissue
(Dworkin et al., 2018; Sweeney et al., 2013b). Following the definition for a CVS+ lesion given by
the NAIMS cooperative (Sati et al., 2016), lesions detected by the MIMoSA model that are smaller
than 3 mm in any plane are removed from candidacy.
3.2.3. Lesion boundary determination
Thresholding of the lesion probability map often results in anatomically distinct lesions being con-
nected by ambiguous boundary voxels. For these lesions to be properly assessed for CVS, the
proposed algorithm addresses this pseudo-confluence through a recently described technique that
removes voxels that are connecting anatomically distinct lesions (Dworkin et al., 2018). The tech-
nique works by finding regions in which the texture of the lesion probability map resembles the
center of a lesion. Therefore, the centers that it produces are maintained and used for investigating
CVS for the remainder of this algorithm. Further detail on the implementation of this method can
be found in the original publication (Dworkin et al., 2018).
As the NAIMS guidelines call for the exclusion of confluent lesions, in some cases of true conflu-
ence this step may represent a deviation from those recommendations. Yet it is important to note
that many lesions that would be judged as discrete by expert raters are often merged by automated
segmentation methods (Oguz et al., 2018). This can result in drastic and unrealistic degrees of
pseudo-confluence in automated lesion masks, sometimes resulting in 50 or more distinct lesions
being merged into fewer than 10 lesion components (Dworkin et al., 2018). Thus, relying on auto-
mated determinations of confluence in automated lesion masks would likely result in the exclusion
of many or most eligible lesions.
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3.2.4. Periventricular lesion exclusion
The density and branching nature of veins near the ventricles makes assessment for CVS difficult
in periventricular lesions, especially in cases where more than one distinct vein traverses the lesion.
For this reason, the NAIMS Cooperative recommends excluding lesions with more than one vein or
with branching veins (Sati et al., 2016). The proposed algorithm addresses this consideration by
excluding periventricular lesions from consideration, as periventricular lesions typically contain mul-
tiple veins. This exclusion is done by performing tissue-class segmentation on the T1 volumes (for
the application to data, this study used the FAST algorithm in the FSL toolbox; Zhang, Brady, and
Smith, 2001), expanding the cerebrospinal fluid (CSF) region of the brain by 3mm, and eliminating
lesions from the lesion-center mask that overlap with the expanded CSF region. The choice of a
3mm expansion was made based on visual inspection of randomly selected T2*EPI volumes, for
which 3mm appeared to include most of the branching vein structure discussed in the consensus
statement, without removing too much of the deep white matter. Notably, although this technique
excludes periventricular lesions, it does not exclude other lesions that may have multiple veins.
This represents a second deviation from the NAIMS recommendations, which could potentially be
addressed by future advances in methods for segmenting and counting distinct veins.
3.2.5. CVS permutation procedure
In lesions that contain central veins, one would expect above-average coherence between voxels’
centrality within the lesion and their vesselness score. The proposed permutation procedure takes
advantage of that expectation to examine the degree to which a lesion’s most vein-like voxels are
more concentrated in the lesion’s center than one might expect to observe by chance. First, a
vein-center coherence score for lesion j in patient i’s scan, Cij , is calculated by summing over the
products of each voxel’s distance-to-nearest-lesion-boundary (i.e., centrality) score, dijv, and its




dijv ⇤ fijv, (3.1)
where V is the set of all voxels in lesion j. Thus, higher values of this score indicate that the
highest vesselness values within the lesion tended to occur in the same voxels as the highest
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centrality values.
To determine the degree to which this score deviates from chance in cases where there is no
biological correspondence between vesselness and centrality, a lesion-specific null distribution of
coherence scores is created using 1000 random permutations. For each permutation, p, the ves-
selness scores of the voxels in lesion j are randomly resampled without replacement, yielding a






dijv ⇤ fijr. (3.2)
This permutation procedure is performed 1000 times, resulting in a sample of 1000 null coherence
scores. The lesion-level CVS probability, ⇡ij , is then calculated as proportion of chance (null-






I[C⇤ijp < Cij ]. (3.3)
To obtain a subject-level CVS biomarker,  i, these probabilities are averaged over all lesions ob-







where NL is the number of candidate lesions in patient i’s scan. The biomarker,  i, can be inter-
preted similarly to the proportion of the patient’s lesions that demonstrate CVS.
3.2.6. Semi-automated adjustment
Though fully-automated lesion segmentation models can be used in the CVS detection pipeline
to create a fully-automated algorithm, upstream errors in lesion segmentation have the potential to
add noise and error to the resulting CVS estimates. For cases in which a given lesion segmentation
model is not well-calibrated, or is being applied to data from a new scanner or hospital, such errors
can be mitigated by manual cleaning of the lesion segmentation maps. Henceforth in the paper,
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we refer to CVS detection applied to cleaned lesion segmentation maps as resulting from a “semi-
automated” algorithm.
3.2.7. Implementation and software
To accompany this article, code for the central vein detection algorithm has been made freely
available online (github.com/jdwor/cvs). The file centralveins presegmented.R, contains code
to run CVS detection on a probability map and a vein map. The choice to implement only the
later stages of this procedure serves to improve functionality across different sites and scanners,
for which researchers and clinicians may have preferred pipelines for preprocessing and lesion
segmentation. The file ExampleCode.R provides a demonstration of how central vein detection
would be carried out in hypothetical data. Finally, a third file, helperfunctions.R, provides additional
functions used within the previous two files.
3.3. Validation in real data
3.3.1. Data and preprocessing
For this study, data were analyzed for 40 research participants recruited from the University of Ver-
mont neurology clinic as part of a study aiming to improve diagnostic specificity for MS (Solomon
et al., 2017b). Participants were between 20 and 67 years of age, and 37 were female. 10 had
MS and no comorbidities known to produce MRI white matter abnormalities; 10 had MS and co-
morbidities known to produce MRI white matter abnormalities; 10 had migraine with MRI white
matter abnormalities and no other white matter comorbidities; and 10 were previously incorrectly
diagnosed with MS and had MRI white matter abnormalities and a variety of diagnoses.
Whole-brain 3D T2-FLAIR, T1, and T2*-EPI (Sati et al., 2014) volumes were acquired in a 3 tesla (T)
Philips dStream MRI scanner with a 32-channel head coil. FLAIR and T1 volumes were obtained
with 1-mm isotropic resolution, and T2*-EPI volumes were obtained with 0.55-mm isotropic reso-
lution. N4 bias correction (Tustison et al., 2010b) was performed on all images, and the T2-FLAIR
volume for each participant was interpolated to a voxel size of 1 mm3 and rigidly co-registered
to the T1 volume. Extracerebral voxels were removed from the T1 volume using a skull-stripping
procedure (Carass et al., 2007), and the brain mask was applied to the T2-FLAIR volume.
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3.3.2. Motion assessment
Since head motion might occur during the T2*-EPI scan, potentially producing uninterpretable im-
ages, each participant’s T2*-EPI scan was manually rated for motion in the relevant white matter
regions. Scans were scored from 1 to 5, where 1 indicated “perfect, no artifacts and excellent signal-
to-noise,” 2 indicated “only one minor artifact that does not obscure any vessels in supratentorial
white matter,” 3 indicated “more than one artifact that do not obscure any vessels in supratentorial
white matter,” 4 indicated “more than one artifact that do obscure some vessels in supratentorial
white matter,” and 5 indicated “severe artifacts or bad signal-to-noise that do obscure most vessels
in supratentorial white matter.” The impact of motion on CVS estimates is assessed and discussed
in a later section.
3.3.3. Performance assessment
As CVS shows great promise as a diagnostic biomarker, the performance of this algorithm in dis-
tinguishing between MS and non-MS cases was of primary interest. To determine whether the
automated biomarkers,  i and  si , replicate the findings from previous work that the distribution of
manually adjudicated central vein proportion differs between MS and its mimics, t-tests were used
to compare the automated CVS values for MS and non-MS cases. To determine the diagnostic
utility of  i and  si , the area under the curve (AUC) values of the receiver operating characteristic
(ROC) curves were estimated. The presence of a difference in performance between of  i and
 
s
i was tested with DeLong’s test for comparing the areas under correlated ROC curves (DeLong,
DeLong, and Clarke-Pearson, 1988), using the pROC package in the R statistical environment (R:
A Language and Environment for Statistical Computing 2015; Robin et al., 2011). Sensitivity and
specificity were calculated using the 40% cutoff (Tallantyre et al., 2011), under which inflamma-
tory demyelination is diagnosed if 40% or more of white matter lesions exhibit CVS, as well as the
more recently proposed 50% cutoff (Maggi et al., 2018). Additionally, locally optimal cutoffs were
determined, and their sensitivity and specificity values were compared to those obtained using
established cutoffs.
Finally, these cutoffs were compared to the performance of proportion cutoffs applied to manual
determinations of CVS in previous research (Maggi et al., 2018; Mistry et al., 2016; Tallantyre et
al., 2011), as well as the performance of three recently proposed clinical decision rules that do not
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require the assessment of the full set of lesions in a scan. The first such rule, referred to as the
rule of 6 (Mistry et al., 2016), states that inflammatory demyelination is diagnosed if there are more
than six lesions with CVS, or if more than half of lesions show CVS. The second and third, referred
to as select3 (Solomon et al., 2016b) and select3* (Solomon et al., 2017b), state that inflammatory
demyelination is diagnosed if CVS is found in at least 2 of 3 lesions pre-selected on T2-FLAIR and
FLAIR* (Sati et al., 2012) imaging, respectively.
Figure 3.2: Performance of patient-level central vein sign (CVS) biomarker. Left and middle
panel show boxplots of the fully-automated biomarker and semi-automated biomarker, respectively,
across diagnostic groups. Right panel shows the ROC curves for differentiating MS and non-MS
patients using the fully-automated and semi-automated biomarkers.
3.3.4. Results
Automated CVS detection was performed on these participants, using the algorithms and software
packages described in the previous section. Two-sample t-tests were run to determine whether
the automated CVS scores differed between the 20 MS and 20 non-MS cases. In both the fully-
automated (MMS = 0.53, SDMS = 0.18; Mnon MS = 0.34, SDnon MS = 0.12; p < 0.001) and
semi-automated (MMS = 0.57, SDMS = 0.22; Mnon MS = 0.28, SDnon MS = 0.15; p < 0.001)
variants of the algorithm, the within-patient average CVS probabilities were higher in patients with
MS compared to patients without MS. See Figure 3.2 for breakdowns across all four groups.
To determine the diagnostic utility of the automated biomarkers,  i and  si , ROC curves were
estimated, and their AUCs were calculated. For the fully-automated case,  i yielded an AUC of
0.81 (Figure 3.2). Based on the 40% rule, applying a cutoff of 0.40 to  i yielded a sensitivity of
0.70 and a specificity of 0.63. Based on the 50% rule, applying a cutoff of 0.50 to this biomarker
yielded a sensitivity of 0.55 and a specificity of 0.89. Two locally optimal cutoffs appear to occur at
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0.35, at which sensitivity was 0.85 and specificity was 0.63, at 0.46, at which sensitivity was 0.60
and specificity was 0.84.
For the semi-automated case,  si yielded an AUC of 0.87 (Figure 3.2). Applying a cutoff of 0.40
to  si yielded a sensitivity of 0.75 and a specificity of 0.74. Applying a cutoff of 0.50 yielded a
sensitivity of 0.60 and a specificity of 0.95. A locally optimal cutoff for  si appears to occur at 0.46,
at which sensitivity was 0.75 and specificity was 0.95. Although the manual lesion tuning appeared
to produce marginally improved performance in the semi-automated case, no significant difference
was found using DeLong’s test (Z = 0.85, p = 0.20).
Though the sample is too small to rigorously assess the effect of motion artifact on the algorithm’s
performance, preliminary results suggest that a lack of robustness to motion may partially explain
the algorithm’s relatively modest performance relative to manual raters. Specifically, when using
only the subset of data with motion ratings  3, the AUC values for the fully- and semi-automated
cases are 0.89 and 0.91, respectively (compared to 0.81 and 0.87) on the full sample). Figure 3.3
shows the biomarker-by-group boxplot for low- and high-motion subsets of the data.
Figure 3.3: Effect of motion on the performance of patient-level central vein sign (CVS) biomarker.
Top row shows biomarker-by-group boxplots for scans with a motion score less than four. Bottom
row shows biomarker-by-group boxplots for scans with a motion score of four or five.
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3.4. Maintaining spatial vein structure
Importantly, though the proposed method appears to have promising utility at the patient level, the
current lesion-level permutation procedure ignores clear spatial structure in the intensities of the
Frangi vesselness map. Preliminary simulations suggest that roughly 15% of non-CVS lesions may
be incorrectly designated as CVS lesions under this procedure (compared to the nominal 5% rate
under spatial independence). Though methods have been proposed for performing permutations
that respect the spatial structure of brain maps (e.g., Burt et al., 2020), vesselness maps do not
adhere to the smooth spatial autocorrelation structures that can be easily modeled. To fill this gap,
future work should focus on developing methods for permuting the location of structures with sharp
boundaries and anisotropic spatial correlation structures.
3.5. Discussion
Preliminary studies have proposed and validated CVS as a promising biomarker for differentiation
MS from other diseases that cause MRI white matter abnormalities (Sati et al., 2016; Solomon
et al., 2016b; Tallantyre et al., 2011). Yet concerns remain regarding the heavy temporal burden
on manual adjudication of CVS, as well as the subjective differences that may arise in response to
variation in adjudicators’ time constraints and intuition. This study sought to address these issues
by introducing an algorithm for automated CVS detection that could in principle, following further
validation, be applied in clinical practice.
In the primary analysis, the algorithm was tested on a cohort of 20 MS (ten with and ten without
other white matter comorbidities) and 20 non-MS (ten with migraine and ten misdiagnosed with
MS) cases. The proposed fully-automated and semi-automated techniques replicated previous
work using manual adjudications (e.g., Kilsdonk et al., 2014; Mistry et al., 2016; Tallantyre et al.,
2011) by demonstrating that proportions of lesions with CVS differ significantly between MS and
its mimics. Additionally, the automated biomarkers,  i and  si , were found to have strong diag-
nostic ability, with AUCs of 0.81 and 0.87 and optimal sensitivity/specificity of roughly 0.75/0.95.
There is also great promise for this algorithm to perform consistently across study sites and MRI
scanners, as in-house preprocessing and lesion segmentation methods can be easily substituted,
and the remaining steps (obtaining vesselness scores, finding lesion centers, and calculating CVS
probabilities) do not require parameter tuning.
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Importantly, the automated biomarkers presented in this study did not perform as well as previously
obtained proportions of CVS based on manual ratings of all lesions in patients’ scans. Specifically,
the 40% and 50% cutoffs used in prior manually rated studies often achieved perfect discrimination
between MS and non-MS cases (Maggi et al., 2018; Tallantyre et al., 2011), which the automated
biomarkers were not able to replicate. However, previous work in a subset of the current sample
showed that manual ratings of all lesions did not fully distinguish migraine patients from patients
with MS and no white-matter comorbidities (Solomon et al., 2016b). This suggests that the non-MS
cases present in the current sample might be more difficult to distinguish from MS using CVS alone
than the non-MS cases present in the studies that did obtain perfect discrimination.
Additionally, although the sensitivity and specificity obtained by these biomarkers were lower than
manually obtained CVS proportions, the biomarkers performed comparably to decision rules that
use only a subset of lesions in a scan (Solomon et al., 2017b). Thus, while automated adjudication
of every lesion in a scan is not yet as accurate as manual adjudication of every lesion in a scan, the
proposed automated method shows promise as an alternative to other clinically feasible methods
for identifying inflammatory demyelination. Further study and refinement of this technique has the
potential to yield biomarkers that are both feasible for use in the clinic and comparable in accuracy
and reliability to CVS proportions obtained by manual adjudication.
There are a number of important limitations to the proposed algorithm. First, biomarker values
were lower than previously reported CVS proportions for MS patients, and higher than previously
reported CVS proportions for non-MS patients. This effect may result from errors in lesion seg-
mentation, which would pull the values of MS and non-MS participants toward each other due to
the assessment of non-informative false-positive lesions. It is also possible that the effect is due
to false-positives or false-negatives in automated CVS assessment. Future work will use manual
lesion-level assessments to tease apart these potential sources.
Although the potential clinical implications of an automated tool for CVS adjudication call for further
study and refinement of such techniques, the current study demonstrates the promising perfor-
mance of a fully automated method for detecting CVS in white matter lesions. To our knowledge,
this is the first automated technique for this challenging aspect of MS diagnosis, and represents an
important step forward toward a specific MRI biomarker for MS lesions.
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CHAPTER 4
A LOCAL MULTIVARIATE DENSITY TEST FOR DETECTING DIFFUSE TISSUE DAMAGE
IN MRI DATA
4.1. Introduction
Clinical interpretation of brain magnetic resonance imaging (MRI) scans has long been a vital tool
for the detection and treatment of neurological diseases (Edelman and Warach, 1993). In the
past few decades, quantification and statistical analysis of data from MRI scans have provided
additional value for not only diagnosing and monitoring such diseases, but also for understanding
brain development (Gu et al., 2015), human behavior (Phelps and LeDoux, 2005), and psychiatric
disorders (Xia et al., 2018). As MRI technology has improved, the data derived from MRI scans
have increased in scale and complexity, with different scanning modalities each producing intensity
values at hundreds of thousands of voxels (3-dimensional pixels) within the brain. To accommodate
the dimensionality of these data, numerous statistical techniques have been developed to allow
researchers to locate and carry out inference on potential disease signatures in these scans (e.g.,
Vandekar et al., 2018; Winkler et al., 2014).
Research using neuroimaging data has largely followed two main frameworks: identifying effects
that occur in specific regions of the brain by conducting voxel-wise or region-of-interest (ROI) anal-
ysis, and identifying and segmenting tissue types that can be located spatially and studied as
cohesive structural units. However, the application of these two frameworks makes the implicit as-
sumption that either, 1) the relevant intensity signature will occur (or not occur) in the same voxels
for every subject (e.g., voxels within the amygdala showing increased blood flow during emotion
tasks), or 2) the relevant intensity signature will be localized in space and will show enough con-
trast with its surroundings to allow for segmentation and subsequent analysis (e.g., tumors and
lesions). We now know, however, that some diseases are characterized by diffuse processes that
can be invisible to these techniques. For example, recent research has found subtle differences
between multiple sclerosis (MS) subjects and healthy controls within the normal-appearing white
matter (NAWM) of the brain, taking the form of slight mean and variance shifts in the intensity of
the NAWM voxels (Lund et al., 2013; Whittall et al., 2002).
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To study these processes, prior work has often relied on univariate or bivariate summary statistics
(e.g., mean, standard deviation, correlation) or histogram analysis to characterize the intensities
present in this tissue. However, when processes are complex or multivariate, these techniques
may fail to capture the true nature of the relevant intensity signatures, and post-hoc efforts to find a
summary statistic sensitive to these effects can introduce substantial bias through implicit multiple
comparisons. When potentially diffuse processes are of interest, quantifying the joint relationships
of voxel intensities across modalities can help fill this methodological gap. Some work has begun
conceptualizing neuroimaging data in this way, such as intermodal coupling (Vandekar et al., 2016)
and spatial correspondence testing (Alexander-Bloch et al., 2018). However, some of these meth-
ods rely on summaries or voxel-wise analyses that have the potential to present only a limited view
of each subject’s multivariate intensity space, and others do not easily scale to higher dimensional
intensity spaces.
Here, we propose treating subjects’ high-dimensional, multi-modal data as being drawn from mul-
tivariate densities. This framework draws ideas from various related works. Specifically, omnibus
tests for detecting overall group differences in multivariate densities can be performed using a
distance-based testing framework (Reiss et al., 2010), yet limited information is obtained from such
an omnibus test. When more specific quantification of differences is desired, histogram analysis
has typically been used in neuroimaging to quantify the shape of voxel intensity densities (e.g.,
Giulietti et al., 2018; Mascalchi et al., 2018). However, such histogram analysis methods focus
on univariate densities from a single imaging modality and rely on summary values like peak loca-
tions and skewness. When joint densities across multiple modalities are of interest, researchers
would likely learn more from local tests performed at specified points within the density space. Prior
research has proposed a procedure for local testing across two group-level multivariate densities
(Duong, 2013), utilizing kernel density estimators (KDEs) and leveraging their known asymptotic
behavior to develop the test. However, in the context of neuroimaging, the local comparison of two
group-level densities represents a special case where two subjects are being compared directly
and the only source of uncertainty is the variance arising from the KDE.
This study seeks to extend these existing methods to the setting in which densities arise at the
subject level, and differences in the local means of group-specific densities are of interest. A similar
context was explored in a previous applied study, in which differences in subject-level bivariate
33
densities were detected using cluster-extent analysis (Zhang et al., 2010). In the current study, we
build on that work by developing the multi-modal density test (MMDT), a formal test for local group
differences in subject-level multivariate densities, and describing its asymptotic and small-sample
properties. In Section 4.2, we introduce the test statistic and discuss its asymptotic properties. In
Section 4.3.1, we conduct simulation studies to investigate performance of the local test as the
number of subjects per group and the number of datapoints per subject vary. In Section 4.3.2, we
simulate the performance of four potential multiple comparison adjustments when conducting the
MMDT over a grid of points within the density space. Finally, in Section 4.4, we apply the MMDT to
MRI data from subjects with multiple sclerosis and subjects with other conditions that have similar
MRI presentations, in order to investigate possible differences in thalamic intensity profiles.
4.2. Proposed local testing method
We seek to investigate local differences in d-dimensional multivariate densities fi, i = 1, . . . , n, be-
tween two groups. As this work focuses on the application to neuroimaging data, the d-dimensional
multivariate space can be thought to refer to the space of voxel intensities across d different imag-
ing modalities. Let si 2 {0, 1} be a binary group indicator for subject i. Further, define group
A = {i : si = 0} and group B = {i : si = 1}. We assume each subject has a subject-specific
density fi, so that fi(x) represents the density of the ith subject evaluated at a given point, x 2 Rd.
Given the presence of between-subject variability in the relative composition of different voxel phe-








A(x), i 2 A
F
⇤
B(x), i 2 B.
(4.1)
Assuming that the densities fi are bounded and continuous, it follows that for g 2 {A,B} and
x 2 Rd, F ⇤g (x) has mean µg(x) such that µg(x) < 1, and variance  2g(x) such that 0 <  2g(x) < 1.
At the point x, we are interested in testing the local hypothesis H0(x) : µA(x) = µB(x). If we could
observe the densities, fi(x), directly and without noise, we could estimate µA(x) and µB(x) by
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where ng is the sample size of group g 2 {A,B}.
However, in practice we do not directly observe subjects’ densities fi. Instead, for subject i, we






























Here, X(1) represents voxel 1, which is characterized by d different intensity values derived from d
different imaging modalities. Using the observed voxels, we can obtain the kernel density estimate







where K is the kernel function with KHi(x) = |Hi| 1/2K(H
 1/2
i x) and Hi is a bandwidth matrix for
subject i. For an individual kernel density estimate, we assume that:
1. the true density fi(x) is bounded and continuous,
2. the bandwidth matrices, Hi = Hi(vi), represent a sequence of positive definite matrices in
which the elements of Hi ! 0 and v 1i |Hi| 1/2 ! 0 as vi ! 1,









Under these conditions, prior work (Parzen, 1962; Wand, 1992) has shown that f̂i(x;Hi)
d!
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N(fi(x),!i) as vi ! 1, where !i = vi|Hi| 1/2R(K)fi(x). While these classical proofs of asymp-
totic normality relied on an assumption of independence, recent work has extended those results
to show that asymptotic normality holds for sequentially (Dedecker and Merlevede, 2002) and spa-
tially (El Machkouri, 2011) dependent data. Thus, as vi ! 1, we can consistently estimate µg(x)
by






Due to the uncertainty imposed by the KDE, additional variance, !i, is imposed on the subject-level
densities. Yet because !i ! 0 as vi ! 1, the target variance in each group,  2g(x), can still be









Finally, under the local null hypothesis H0(x) : µA(x) = µB(x), we can construct a test statistic









Allowing for unequal variances, this test takes the form of Welch’s two-sample t-test. The statistic,
t(x), then follows a t distribution with   degrees of freedom, and converges in distribution to N(0, 1)
















Notably, the performance of this test depends on large samples of within-subject observations, as
well as either a large number of subjects or relatively symmetric group-level data. While the limit
n ! 1 in this context bears the familiar interpretation of the sample size going to infinity, the
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limit vi ! 1, which indicates the number of voxels per subject going to infinity, is less standard.
In practice, this assumption can be thought to represent improvements in MRI technology, which
have led to voxels representing smaller and smaller spatial regions over the past few decades. To
understand the importance of this limit for the method’s validity, in the following section we describe
and conduct simulation studies across finite voxel and sample sizes.
4.3. Simulation study
To determine the finite-voxel and finite-sample performance of the MMDT procedure, we conducted
two simulation studies. The first examined the performance of the local test conducted at a specific
point in the multivariate density space, x, to assess the validity of the test statistic’s null distribution
and determine its power. The second examined the performance of the method when applied
over a grid of points across the density space, to characterize the full exploratory use case and
illustrate potential methods for accounting for multiple comparisons in this setting. Both studies
were comprised of several scenarios to examine how the findings were affected by features of the
data generating distribution and user choices required by the method.
For both simulation studies, observations for each subject were drawn from a mixture of a shifted
and scaled bivariate beta distribution and a bivariate normal distribution. This set-up thus reflects a
scenario in which voxels each have two associated intensity values (d = 2 modalities). Group differ-
ences were implemented in the correlation structure of the bivariate beta distribution, while the form
of the bivariate normal distribution was consistent across groups (see 4.1). Inverse transform sam-
pling was used on bivariate normal observations in order to simulate bivariate beta observations
with a specific correlation structure.
We chose this set-up, instead of a single bivariate normal distribution, for two primary reasons: 1)
The mixture distribution allowed us to isolate specific regions in which there is a group difference,
while also examining the performance of the test in regions where there is no group difference.
Specifically, since the scaled bivariate beta distribution has finite support, its use creates a bounded
false null region. Had a single bivariate normal distribution been used, any group difference in its
covariance structure would create a globally false null. In short, the chosen scenario allows us to
consider both a mixed null case and a global null case. 2) The mixture distribution gives a scenario
in which simple univariate and bivariate summary statistics are not well-suited to characterize the
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Figure 4.1: Design of the simulation studies. (A) Illustration of the voxel intensity generating distri-
butions across values of ✓. (B) Visualization of the expected group differences in densities across
simulation scenarios. The first column shows the scenario in which ✓ values are drawn from the
same beta distribution for subjects in group A and group B. Second, third, and fourth columns show
the scenarios in which ✓ values are drawn from increasingly divergent beta distributions for subjects
in group A and group B.
group difference. This then demonstrates a case where the proposed method would be able to
capture on group differences that are obscured by subject-level means or correlations.
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r = 0.7 ⇤ ✓,
✓ ⇠ B(↵g, g).
For each subject, a value for ✓, the parameter that drives the correlation of the bivariate beta
observations, r, was drawn from a beta distribution with group-specific values for parameters ↵
and  . When ↵A 6= ↵B and/or  A 6=  B , this parameter induced differences in the groups’ mean
bivariate densities and subject-specific variation within group.
4.3.1. Testing at a single point
For the first simulation, four data generating scenarios were included. The first, designed to ex-
amine type I error, specified ↵A = ↵B = 2 and  A =  B = 5, meaning that there was no group
difference in the correlation structure of the bivariate beta observations (i.e., a global null case).
The remaining three simulation scenarios examined the test’s power (in the false null regions) and
type I error (in the true null regions) for varying degrees of discrepancy between group densities. In
the three scenarios, ↵A =  B = 5, and ↵B and  A were set at 4, 3, and 2, respectively.
Each simulation scenario was repeated with a variety of between-subject sample sizes, n, and
within-subject observations, v. The effect of the number of subjects per group on type I error and
power was tested using nA = nB = 20, 30, 50, and 80. The effect of the number of observations
per subject was tested using vi = 500, 1000, 2500, 5000, and 10000 for all i. Each scenario (i.e.,
combination of n and v = vi) was run 1000 times. For the presented simulations, the ks package in
the R Statistical Environment was used to compute subject-level kernel density estimators (Duong,
2007; R Core Team, 2018). Kernel density estimators were calculated using normal kernels, and
bandwidth matrices were empirically estimated using the plug-in estimators proposed by Duong
and Hazelton (Duong and Hazelton, 2003). Results of the simulation studies are presented for
four exemplary points within the bivariate density space: [x1 =  2;x2 = 2], [x1 =  1.5;x2 = 1.5],
[x1 = 0;x2 =  1], and [x1 =  2.5;x2 =  0.1]. These points were selected a priori to represent
different density levels (in both type I error and power analyses) and different degrees of group
differences (in power analyses).
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For the global null case, in which ↵A = ↵B = 2 and  A =  B = 5, type I error was controlled at ↵ =
0.05 for all four points, across all combinations of n and v. This suggests that the distribution of the
test statistic is valid in settings with small-to-medium sample sizes and subject-level observations
(Fig. 4.2, column 1). Importantly, this was true when the correlation-generating parameter, ✓, was
drawn from a skewed distribution.
Simulation results for the three scenarios in which there were group differences reveal the interplay
between sample size and subject-level observations in obtaining adequate power. Figure 4.2 (row
1, columns 2-4) represents the power of the local test for a point at which one group tends to have
a low density of voxels, while the other has a moderate density. Here, sample size appears to play
a greater role than subject-level observations in obtaining power to detect the difference. Row 2
(columns 2-4) represents a point at which there is a meaningful group difference, but densities tend
to be relatively high in both groups and the region of difference is somewhat narrow. Here, the num-
ber of subject-level observations appears to play a slightly larger role in obtaining adequate power,
potentially suggesting that accurate kernel density estimation is important for detecting group dif-
ferences in regions where the difference is more localized. Row 3 (columns 2-4) represents a point
at which there is no true difference in the data generating distribution between groups. Unlike the
regions illustrated in row 1 and row 2, the detection of significant differences here represents type I
error, not power. This row demonstrates that regardless of sample size or number of within-subject
observations, the type I error rate is controlled at 0.05.
Finally, row 4 (columns 2-4) represents another point at which there is no true difference between
groups. However, unlike the point shown in row 3, this point is adjacent to the false null region.
The figure shows that in this case, a low number of subject-level observations (voxels) results in
type I error above the nominal rate of ↵ = 0.05, while the type I error rate tends towards 0.05 as
the number of subject-level observations increases. The inflated type I error rate in this region is
an artifact of the smoothing that results from the KDE in the presence of low numbers of observa-
tions. Specifically, in the presence of low numbers of voxels the plug-in bandwidth estimators utilize
observations from a wider range of locations to estimate local densities, which has the potential to
smooth differences from the false null region (the gray box in the upper left hand corner) into the
true null region. This issue suggests that the strict local interpretation of the test may be limited in
situations in which few voxels are analyzed per subject, though importantly, this effect is only seen
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very close to the border of the false null region.
Figure 4.2: Type I error and power of MMDT applied to a single point. Columns represent the four
simulation scenarios, in which ✓ values are either drawn from the same beta distribution for subjects
from both groups (column 1) or increasingly divergent beta distributions (columns 2-4). Rows show
the rate at which the local null hypothesis is rejected at four exemplary points in the density space.
Rows 1 and 2 show points at which there is a true group difference in the generating distribution.
Rows 3 and 4 show points at which there is no true group difference in the generating distribution.
Each plot shows the rejection rate as a factor of the number of voxels per subject and the number
of subjects per group.
4.3.2. Testing over a grid
In most cases, researchers will not have a limited set of points at which they wish to test for group
differences. Instead, a more common use case will likely be to conduct an exploratory test for
differences over a dense grid of points throughout the multivariate space. To conduct this type of
analysis, the issue of multiple comparisons must be addressed (e.g., conducting the MMDT on a
151x151 grid yields 22,801 individual test statistics). Countless methods have been proposed to
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adjust for multiple comparisons in high dimensional cases. Here, we will compare the performance
of four methods - two for controlling the family-wise error rate (FWER) and two for controlling the
false-discovery rate (FDR) - and discuss the benefits and limitations of each.
For controlling FWER, we apply the max-t procedure (Westfall and Young, 1993) and threshold-
free cluster enhancement (TFCE) procedure (Smith and Nichols, 2009). The max-t procedure
calculates pointwise significance by comparing the test statistics in the observed comparison to
a distribution of maximum test statistics obtained through permutation of group labels. This test
is well-suited to account for dependence between test statistics, and is primarily suited for testing
the global null (i.e., all hypotheses are true). Its power and ability to control FWER in the mixed
null case (i.e., some hypotheses are false) are less clear. TFCE more explicitly accommodates
spatial dependence between test statistics, as would be expected when testing multiple points
across the density space. TFCE incorporates spatial dependence by augmenting pointwise test
statistics with their membership, or lack thereof, in spatial clusters. Forgoing the pre-specification
of a specific cluster-forming threshold, TFCE’s augmentation incorporates information from the full
range of possible thresholds. Like max-t, TFCE compares the resulting pointwise scores to the
distribution of the maximum scores under permutation of group labels, and is also primarily suited
for testing the global null. Its incorporation of spatial extent makes it likely to be more powerful than
max-t in this context, but its ability to control FWER under a mixed null depends on the assumption
of subset pivotality, which is almost certainly violated due to the smoothness of the kernel density
estimates.
For controlling FDR, we apply both the Benjamini-Hochberg (Benjamini and Hochberg, 1995) and
Benjamini-Yekutieli (Benjamini and Yekutieli, 2001) procedures. Benjamini-Hochberg (henceforth
’BH’) is the classical method for FDR control, in which p-values are ordered from small to large and
significance is determined for ordered test i by whether or not the p-value, pi  ↵ ⇤ im , where ↵
is a pre-selected significance level, and m is the total number of tests (Benjamini and Hochberg,
1995). This method controls the FDR under independence or positive regression dependence
of individual p-values. Benjamini-Yekutieli (henceforth ’BY’) is a more conservative adjustment to
the BH procedure that allows for arbitrary dependence between p-values (Benjamini and Yekutieli,
2001). Since positive dependence is a reasonable assumption in this context (i.e., differences in
one region are positively linked with the presence of differences in another region), we expect BY
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may be overly conservative. Importantly, FDR is best defined in the mixed case, in which some null
hypotheses are false. In the global null case, in which all null hypotheses are true, FDR is equal to
FWER.
Simulated comparison of these four adjustment techniques was carried out using the same data
generation procedure described previously. Results are presented for the situation when nA =
nB = 30, with the number of voxels per subject, vi, varied over 500, 1000, 2500, 5000, and 10000. To
assess FWER under a global null, the scenario in which ↵A = ↵B = 2 and  A =  B = 5 was used.
To assess power, FWER under the mixed null, and FDR under the mixed null, the scenario in which
↵A =  B = 5 and ↵B =  A = 3 was used. Each scenario was tested 1000 times, and the corrected
p-values for each point were obtained using each of the four procedures described above.
Figure 4.3 shows the power at two exemplary points (row 1), FWER and FDR in the mixed null case
(row 2), and FWER in the global null case (row 3). Row 1 shows increasing power for all multiple
comparison procedures as the number of voxels increases. Taking the case of 5000 voxels as an
example, power is 0.82 with max-t correction, 0.93 with TFCE, 0.98 with BH, and 0.88 with BY at
[x1 =  2, x2 = 2] (shown in red), and 0.24, 0.62, 0.82, and 0.48, respectively, at [x1 =  1.5, x2 =
1.5] (shown in blue). Consistent with expectations, TFCE obtains additional power above max-
t by incorporating cluster information, and BH obtains additional power both FWER methods by
controlling FDR. BY, due to its conservative nature, obtains power somewhere between the TFCE
and max-t procedures.
Row 2 shows results for the mixed null case, in which hypotheses in the upper square of the density
space are false, and hypotheses in the rest of the density space are true. Here, the number of
subject-level observations does not seem to impact either FWER or FDR. Across these values, the
average FWER is 0.043 using max-t and 0.081 using TFCE, while the average FDR is 0.028 using
BH and 0.003 using BY. The lack of FWER control under TFCE in the mixed case is partly due to
its lack of a clear pointwise interpretation; TFCE only allows for an interpretation along the lines
of, “there exists a cluster containing this point for which we reject the null, and we conclude that
there is signal for at least one point within that cluster.” Thus, while TFCE does provide increased
power over max-t, its lack of strict FWER control in the mixed case and its lack of clear pointwise
interpretation make it perhaps less than ideal in this context. As expected, BH controls FDR slightly
below the nominal rate, while BY is overly conservative. Row 3 shows the results for the global null
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Figure 4.3: Type I error and power of MMDT applied over a grid. Columns represent the four mul-
tiple comparison methods being compared. Row 1 shows the power for two exemplary points at
which there is a true group difference in the data generating distribution. Row 2 shows the FWER
(columns 1 and 2) and the FDR (columns 3 and 4) in the mixed null case, with the purple box
highlighting the region of the density space at which there is no true group difference in the data
generating distribution. Row 3 shows the FWER in the global null case, with the green box high-
lighting the full density space, across which there is no true group difference in the data generating
distribution.
case, in which all hypotheses are true. Across subject-level observation counts, the average FWER
is 0.053 using max-t, 0.052 using TFCE, 0.012 under BH, and < 0.001 for BY, demonstrating that
FWER error is controlled for all four methods under a global null.
4.4. Application: Thalamic intensity profiles in MS
Multiple sclerosis is an autoimmune inflammatory demyelinating disease of the central nervous
system. MS is typically characterized on MRI by lesions in the white-matter of the brain (Trip, 2005),
and is clinically characterized by cognitive and motor impairment (Chiaravalloti and DeLuca, 2008;
Kurtzke, 1983). While neuroimaging research in MS has largely focused on the characterization of
lesional and axonal damage in the white matter (Barnett et al., 2016; Trip, 2005), a growing body
of work has also shown that loss of gray matter tissue (referred to as “atrophy”) is also common
in MS (Minagar et al., 2013). The thalamus, one of several gray matter structures in the brain,
appears to be particularly relevant in MS pathology. Studies have found that MS subjects show
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greater rates of thalamic atrophy than healthy controls (Houtchens et al., 2007), MS subjects have
differing spatial patterns of thalamic atrophy compared to healthy controls (Fadda et al., 2019), and
specific thalamic markers are related to worse clinical outcomes within MS subjects (Rocca et al.,
2010).
Despite the prevalence of literature comparing the thalami of MS subjects to those of healthy con-
trols, less is currently known about whether and how thalamic tissue differs between subjects with
MS and those with conditions like migraine or small-vessel ischemia that mimic MS on other MRI
measures. Notable recent work in this area has found that thalamic volume tends to be lower in MS
subjects than subjects with MS mimics (Solomon et al., 2017a). This difference potentially implies
higher rates of atrophy within MS, and suggests that that differences may also be present within
thalamic tissue prior to atrophy. Here, we extend these findings by attempting to flexibly charac-
terize differences in the thalamic voxel intensity profiles between subjects with MS and those with
MS mimics. The existence of such differences could give insight into the underlying processes that
facilitate increased atrophy in MS.
4.4.1. Data description
Thirty-nine subjects were recruited from the University of Vermont neurology clinic as part of a study
seeking to improve differential diagnostic accuracy in MS (Solomon et al., 2017b). Participants
were between the ages of 20 and 67, and 36 were women. Ten had MS and had no additional
conditions associated with white matter abnormalities; 10 had MS and at least one other condition
associated with white matter abnormalities; 10 had migraine with white matter abnormalities visible
on MRI; and 9 were previously incorrectly diagnosed with MS and had white matter abnormalities
on MRI. All subjects in the sample presented with at least one white matter lesion on MRI. Details
of the image acquisition have been previously published (Solomon et al., 2017b) and are briefly
summarized below.
Whole-brain 3D T1-weighted (T1) and fluid-attenuated inversion recovery (FLAIR) volumes (see
Fig. 4.4A) were acquired on a 3 Tesla (3T) MRI scanner (Philips dStream, 32-channel head coil).
T1 and FLAIR represent two common types of MR image that can be obtained by varying the radio
frequency pulses of the scanner, producing differences in contrast and highlighting different qual-
ities of the tissue. Both sequences were obtained in a single scanning session for each subject,
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and were acquired with 1 mm isotropic voxel sizes. All images were preprocessed prior to analysis.
Inhomogeneity was corrected using the N4 bias correction method (Tustison et al., 2010a), sub-
jects’ FLAIR volumes were rigidly co-registered to their T1 images using a Lanczos windowed sinc
interpolator, and extracerebral voxels were removed using multi-atlas skull stripping (Doshi et al.,
2013). Finally, the thalamus was segmented from each subject’s T1 volume using joint label fusion
(Wang et al., 2013).
4.4.2. Statistical analysis
For each subject, voxels’ T1 and FLAIR intensity values were evaluated within the thalamus (Fig.
4.4A-B). Intensities were Z-score normalized to remove marginal mean and variance differences
across subjects and isolate differences in the joint intensity distributions. Approximately 28,000
thalamic voxels were included per subject (M = 27748, sd = 3283). Subjects’ KDEs were created
using a normal kernel with plug-in bandwidth estimators (Duong and Hazelton, 2003), yielding
multivariate densities with d = 2 modalities (T1 and FLAIR; see Fig. 4.4B). MMDT was carried out
over a 151x151 grid within the density space from [ 3, 3] to [3, 3]. This range corresponds to the
region of the density that includes voxels with normalized T1 and FLAIR values between  3 and 3,
capturing roughly 98% of all voxels (M = 0.98, sd = 0.006). Significance was established using the
Benjamini-Hochberg procedure (Benjamini and Hochberg, 1995).
4.4.3. Results
Testing revealed significant differences in the thalamic voxel intensity profiles between MS and
nMS subjects. Specifically, MS subjects tended to have higher densities along the FLAIR =  T1
line, and lower densities in regions of relatively high or low intensity on both T1 and FLAIR (Fig.
4.4C). This result indicates that voxels’ T1 and FLAIR intensities within the thalami of MS subjects
tended to show more coherence than those of non-MS subjects. A test for group differences in the
subject-level correlations between T1 and FLAIR intensities showed some evidence that T1/FLAIR
correlations may be slightly higher in MS subjects, though the findings were inconclusive (t37 = 1.48,
p = 0.15) prior to removal of an outlier in the MS group (t36 = 2.42, p = 0.02). Though the MMDT
findings presented here may reflect a straightforward difference in within-subject correlations, the
lack of prior knowledge regarding which summary statistic(s) may be relevant in this case makes
the flexibility of the MMDT valuable for detecting and locating such differences. If differences in
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Figure 4.4: Application of the MMDT procedure for testing thalamic intensity profiles. (A) Visualiza-
tion of four example subjects and their T1 and FLAIR volumes, with thalami highlighted in red. (B)
Scatterplots and kernel density estimates for the subjects’ bivariate voxel intensity densities. (C)
Results of the MMDT for detecting density differences between MS and non-MS (nMS) subjects.
Top row shows the test-statistic map across the bivariate density, bottom row shows significant re-
gions following Benjamini-Hochberg correction. (D) Example of MMDT test statistics being mapped
back to subjects’ brain spaces for exploratory visualization.
a specific summary measure were of interest, the nonparametric nature of MMDT would yield
reduced power compared to a direct test of that measure. Thus, this technique is best suited for
the detection of unknown or complex group differences.
Exploratory visualization of voxels’ test statistics within subjects’ brain spaces was conducted to
determine the potential for common spatial patterning of MS-specific intensity profiles (Fig. 4.4D).
This process was carried out by assigning voxels the statistic associated with the region of the mul-
tivariate density space in which their multi-modal intensities were located. Crucially, these statistics
themselves cannot be interpreted in the spatial domain. Instead, the apparent regional partition-
ing of the test statistics suggests the potential for future work that investigates the relevance of
multi-modal voxel intensity profiles within different thalamic subregions.
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4.5. Discussion
In this chapter, we introduced the multi-modal density test (MMDT), a method for detecting local
group differences in subject-level multivariate densities. The method works by taking multivariate
high-dimensional data at the subject level, estimating subject-specific densities (using kernel den-
sity estimation), and testing for mean differences in pointwise density values across a binary group
variable. In the context of MRI research, MMDT allows researchers to investigate differences in
multi-modal voxel intensity profiles, without the assumption that signatures of interest will occur in
the same voxels across subjects (as made by mass univariate hypothesis testing). It also allows for
the naive detection of group-specific multivariate patterns, reducing the need to perform dimension
reduction or select an optimal summary statistic in contexts in which the pattern of interest is not
clear.
While the asymptotic properties of the local test as the number of subjects and the number of
voxels per subject tend to infinity are straightforward, the behavior of the test with finite samples and
relatively few voxels was previously unknown. Thus, we performed simulation studies to investigate
the finite-sample properties. The simulations showed that type I error is generally controlled when
testing at a single point within the density space. However, with very small numbers of subject-level
observations overly smooth kernel density estimates can result in inflated type I error rates along
the boundary of false null regions. The simulations also provide insight into the differential effects
of voxel number and pointwise density on the power of the test at a given location.
Because of the potential value of this method as an exploratory procedure for detecting previously
unknown disease signatures, it is important to be able to simultaneously perform multiple tests
over a grid of points within the multivariate density space. In this context, correcting for multiple
comparisons is vital. Thus, we conducted a simulation study to compare the performance of max-t
correction (Westfall and Young, 1993) and threshold-free cluster enhancement (TFCE; Smith and
Nichols, 2009) for FWER control, as well as Benjamini-Hochberg (BH; Benjamini and Hochberg,
1995) and Benjamini-Yekutieli (BY; Benjamini and Yekutieli, 2001) for FDR control. We found that
all four methods controlled FWER under a global null, for which there were no false null hypotheses
at any point in the density space, while TFCE failed to control FWER under a mixed null (though,
importantly, TFCE does not claim to provide strict pointwise interpretations). BH yielded the high-
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est power of the four methods, followed by TFCE. Due to its control of FDR and high power, we
recommend BH among the four tested multiple comparison methods.
We then applied the MMDT to a dataset of structural MRI volumes in MS subjects and subjects
with other conditions associated with MRI abnormalities, and sought to detect differences between
groups in their voxel intensity profiles within the thalamus. We found significant differences within
several regions of the bivariate T1-FLAIR density space, with MS subjects having higher densities
in regions that followed more tightly along the FLAIR =  T1 line, and non-MS subjects having
higher densities in the upper-right and lower-left quadrants of the joint space. The results gener-
ally suggested that subjects with MS have stronger coherence between T1 and FLAIR intensities
among voxels in the thalamus, possibly indicating that a greater proportion of thalamic intensity
variability in MS subjects is due to underlying tissue biology versus random scanner noise. Fu-
ture work could directly incorporate histology data to better understand the underpinnings of these
differences in the joint T1-FLAIR space.
Several extensions of this method would be valuable areas to explore in future work. First, neu-
roimaging data are often characterized by measurement error arising from voxel resolution, motion,
and even subjects’ hydration level. Future work could investigate how various types of measure-
ment error affect the performance of this method. Additionally, in cases where spatial localization is
of interest, test statistics and p-values from the density space can be visualized in subjects’ scans
by matching specific voxels’ multi-modal intensity values with the relevant region of the density
space. While these values themselves cannot be interpreted spatially, shared localization of group-
specific voxel intensity profiles could be useful for hypothesis generation and motivation of further
research.
The analysis of neuroimaging data has revealed countless insights into disease processes in the
brain, yet common techniques like voxel-wise significance testing, ROI-based analysis, and network
analysis are limited by the assumption that relevant processes will occur in the same locations
across subjects. Here, we posited that the operationalization of multi-modal neuroimaging data
as subject-level multivariate densities has the potential to reveal diffuse or non-localized imaging
signatures, and proposed a method for detecting group differences locally within the density space.
We found that this method controls type I error when applied at a single point, controls the FWER
when applied over a grid, and maintains power for increasing grid sizes. The MMDT represents an
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important new tool for the exploratory analysis of neuroimaging data and other high-dimensional
subject-level data sources.
4.5.1. Code and data availability
An R package for implementing MMDT is available on GitHub (github.com/jdwor/mmdt), and R





5.1. Lesion counting and center detection
In Chapter 2, we introduced a novel technique for obtaining cross-sectional counts of anatomically
distinct lesions, and demonstrate it to be a valid, reliable, and clinically meaningful biomarker for MS
disease status. Utilizing information contained in the Hessian structure of lesion probability maps
produced by automated segmentation methods, this technique counts distinct lesions by identifying
regions that resemble the physiological traits of distinct lesion centers.
Validity of this measure was established by comparing counts obtained at a single time point to gold-
standard counts that incorporated temporal information on lesion development. The proposed count
had a correlation of 0.97 with the gold-standard count, indicating very strong validity of this measure.
A count obtained using the connected components method had only a 0.67 correlation with the
gold-standard, and appeared to strongly underestimate the number of lesions in individuals who
developed more than one or two lesions per year over the course of the study. This underestimation
manifested in a highly significant difference between the connected components counts and the
gold-standard counts in a paired t-test, whereas no difference was found between the proposed
counts and the gold-standard counts. These findings demonstrate that the proposed technique
yields a count that is consistent with the natural history of lesion formation.
Reliability was considered using a rich set of data from the NAIMS Cooperative. In that study, a
clinically and radiologically stable subject was scanned two times at each of seven different sites
across the United States. To judge the reliability of the proposed measure, the lesion count was
obtained for all 14 scans of this subject, and the coefficient of variation of the counts was compared
to that of lesion load in two contexts. In the fully automated comparison, lesion count had a slightly
lower CV than lesion load. This indicates that across repeated scans of the same brain, automated
lesion count is a less variable measure than automated lesion load. In the manually supplemented
comparison, lesion count had a slightly higher CV than lesion load, implying that lesion load is a
slightly less variable measure than lesion count when calculated using expert lesion segmentation
masks. Upon inspection there appeared to be one scan where automated lesion segmentation
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failed, producing an abnormal Hessian structure within the manually segmented lesion mask. With
this scan removed, the CV of lesion count dropped to slightly more than half that of manual lesion
load. This suggests that when automated lesion segmentation methods perform as expected,
lesion count is appreciably more reliable than even manual lesion load, a widely used measure of
disease severity.
Clinically, the lesion count measure appears to be a potentially important addition to commonly
used radiological biomarkers for MS. In a model accounting for lesion load and age, lesion count
was highly significantly associated with EDSS. Interestingly, this association was negative, indicat-
ing that for subjects who have similar lesion load, better outcomes are associated with more (and
smaller) lesions rather than fewer (and larger) lesions. This lends support to the idea that neither
the number of lesions nor the amount of tissue damage alone captures all relevant clinical infor-
mation, and instead suggests they should be considered together. One way to conceptualize the
combination of these metrics is average lesion size, which taps into the degree to which the brain
is capable of halting the growth of lesions and encouraging lesional recovery (Meier and Guttmann,
2003, 2006; Sweeney et al., 2016) after incidence.
To investigate this concept more directly, a measure of average lesion size was created by dividing
lesion load by lesion count. Pearson correlations with EDSS were then compared for the three
biomarkers of lesion load, lesion count, and average lesion size. These findings provided further
support for the combined importance of lesion load and lesion count, with both showing small and
nonsignificant associations with EDSS. However, average lesion size showed a significant positive
association with EDSS, consistent with the notion that the brain’s ability to slow or stop lesion
growth is clinically relevant. These findings point to the importance of considering lesion count in
MS research, and provide further evidence of the validity of the proposed counting technique.
A limitation of the current study is the possibility of alternate explanations of confluence that are not
accounted for in the design of the proposed count. It has been hypothesized that confluent lesions
may occasionally occur as a result of the growth of older lesions, or the expansion of pathological
processes. Future research should consider the degree to which this technique does or does not
characterize these types of confluence as anatomically distinct lesions. Additionally, the current
analyses do not account for the possibility of vascular comorbidity, which is a common and notable
occurence in MS patients. Future work should investigate the performance of this algorithm in the
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presence of vascular lesions.
The lesion count method presented in this chapter has several appealing features, including its
low computational burden and its easy and flexible implementation. Computationally, the counting
algorithm takes less than a minute to run once probability maps are obtained. The speed of the
full technique varies depending on the lesion segmentation method used, but took approximately
25 minutes per subject as presented in this study. In terms of implementation, this method can
be quickly and easily coded in any program capable of calculating the Hessian structure of a 3D
image, a feature included in most image processing packages. It can also be used with any le-
sion segmentation method that yields a probability map, allowing it to be implemented within most
pipelines regardless of preferred segmentation algorithm.
5.2. Towards automated central vein assessment
Preliminary studies have proposed and validated CVS as a promising biomarker for differentiation
MS from other diseases that cause MRI white matter abnormalities (Sati et al., 2016; Solomon
et al., 2016b; Tallantyre et al., 2011). Yet concerns remain regarding the heavy temporal burden
on manual adjudication of CVS, as well as the subjective differences that may arise in response to
variation in adjudicators’ time constraints and intuition. In Chapter 3, we sought to address these
issues by introducing an algorithm for automated CVS detection that could in principle, following
further validation, be applied in clinical practice.
In the primary analysis, the algorithm was tested on a cohort of 20 MS (ten with and ten without
other white matter comorbidities) and 20 non-MS (ten with migraine and ten misdiagnosed with
MS) cases. The proposed fully-automated and semi-automated techniques replicated previous
work using manual adjudications (e.g., Kilsdonk et al., 2014; Mistry et al., 2016; Tallantyre et al.,
2011) by demonstrating that proportions of lesions with CVS differ significantly between MS and
its mimics. Additionally, the automated biomarkers,  i and  si , were found to have strong diag-
nostic ability, with AUCs of 0.81 and 0.87 and optimal sensitivity/specificity of roughly 0.75/0.95.
There is also great promise for this algorithm to perform consistently across study sites and MRI
scanners, as in-house preprocessing and lesion segmentation methods can be easily substituted,
and the remaining steps (obtaining vesselness scores, finding lesion centers, and calculating CVS
probabilities) do not require parameter tuning.
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Importantly, the automated biomarkers presented in this study did not perform as well as previously
obtained proportions of CVS based on manual ratings of all lesions in patients’ scans. Specifically,
the 40% and 50% cutoffs used in prior manually rated studies often achieved perfect discrimination
between MS and non-MS cases (Maggi et al., 2018; Tallantyre et al., 2011), which the automated
biomarkers were not able to replicate. However, previous work in a subset of the current sample
showed that manual ratings of all lesions did not fully distinguish migraine patients from patients
with MS and no white-matter comorbidities (Solomon et al., 2016b). This suggests that the non-MS
cases present in the current sample might be more difficult to distinguish from MS using CVS alone
than the non-MS cases present in the studies that did obtain perfect discrimination.
Additionally, although the sensitivity and specificity obtained by these biomarkers were lower than
manually obtained CVS proportions, the biomarkers performed comparably to decision rules that
use only a subset of lesions in a scan (Solomon et al., 2017b). Thus, while automated adjudication
of every lesion in a scan is not yet as accurate as manual adjudication of every lesion in a scan, the
proposed automated method shows promise as an alternative to other clinically feasible methods
for identifying inflammatory demyelination. Further study and refinement of this technique has the
potential to yield biomarkers that are both feasible for use in the clinic and comparable in accuracy
and reliability to CVS proportions obtained by manual adjudication.
There are a number of important limitations to the proposed algorithm. First, biomarker values
were lower than previously reported CVS proportions for MS patients, and higher than previously
reported CVS proportions for non-MS patients. This effect may result from errors in lesion seg-
mentation, which would pull the values of MS and non-MS participants toward each other due to
the assessment of non-informative false-positive lesions. It is also possible that the effect is due
to false-positives or false-negatives in automated CVS assessment. Future work will use manual
lesion-level assessments to tease apart these potential sources.
Although the potential clinical implications of an automated tool for CVS adjudication call for further
study and refinement of such techniques, the current study demonstrates the promising perfor-
mance of a fully automated method for detecting CVS in white matter lesions. To our knowledge,
this is the first automated technique for this challenging aspect of MS diagnosis, and represents an
important step forward toward a specific MRI biomarker for MS lesions.
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5.3. Multi-modal density test
In Chapter 4, we introduced the multi-modal density test (MMDT), a method for detecting local group
differences in subject-level multivariate densities. The method works by taking multivariate high-
dimensional data at the subject level, estimating subject-specific densities (using kernel density
estimation), and testing for mean differences in pointwise density values across a binary group
variable. In the context of MRI research, MMDT allows researchers to investigate differences in
multi-modal voxel intensity profiles, without the assumption that signatures of interest will occur in
the same voxels across subjects (as made by mass univariate hypothesis testing). It also allows for
the naive detection of group-specific multivariate patterns, reducing the need to perform dimension
reduction or select an optimal summary statistic in contexts in which the pattern of interest is not
clear.
While the asymptotic properties of the local test as the number of subjects and the number of
voxels per subject tend to infinity are straightforward, the behavior of the test with finite samples and
relatively few voxels was previously unknown. Thus, we performed simulation studies to investigate
the finite-sample properties. The simulations showed that type I error is generally controlled when
testing at a single point within the density space. However, with very small numbers of subject-level
observations overly smooth kernel density estimates can result in inflated type I error rates along
the boundary of false null regions. The simulations also provide insight into the differential effects
of voxel number and pointwise density on the power of the test at a given location.
Because of the potential value of this method as an exploratory procedure for detecting previously
unknown disease signatures, it is important to be able to simultaneously perform multiple tests
over a grid of points within the multivariate density space. In this context, correcting for multiple
comparisons is vital. Thus, we conducted a simulation study to compare the performance of max-t
correction (Westfall and Young, 1993) and threshold-free cluster enhancement (TFCE; Smith and
Nichols, 2009) for FWER control, as well as Benjamini-Hochberg (BH; Benjamini and Hochberg,
1995) and Benjamini-Yekutieli (BY; Benjamini and Yekutieli, 2001) for FDR control. We found that
all four methods controlled FWER under a global null, for which there were no false null hypotheses
at any point in the density space, while TFCE failed to control FWER under a mixed null (though,
importantly, TFCE does not claim to provide strict pointwise interpretations). BH yielded the high-
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est power of the four methods, followed by TFCE. Due to its control of FDR and high power, we
recommend BH among the four tested multiple comparison methods.
We then applied the MMDT to a dataset of structural MRI volumes in MS subjects and subjects
with other conditions associated with MRI abnormalities, and sought to detect differences between
groups in their voxel intensity profiles within the thalamus. We found significant differences within
several regions of the bivariate T1-FLAIR density space, with MS subjects having higher densities
in regions that followed more tightly along the FLAIR =  T1 line, and non-MS subjects having
higher densities in the upper-right and lower-left quadrants of the joint space. The results gener-
ally suggested that subjects with MS have stronger coherence between T1 and FLAIR intensities
among voxels in the thalamus, possibly indicating that a greater proportion of thalamic intensity
variability in MS subjects is due to underlying tissue biology versus random scanner noise. Fu-
ture work could directly incorporate histology data to better understand the underpinnings of these
differences in the joint T1-FLAIR space.
Several extensions of this method would be valuable areas to explore in future work. First, neu-
roimaging data are often characterized by measurement error arising from voxel resolution, motion,
and even subjects’ hydration level. Future work could investigate how various types of measure-
ment error affect the performance of this method. Additionally, in cases where spatial localization is
of interest, test statistics and p-values from the density space can be visualized in subjects’ scans
by matching specific voxels’ multi-modal intensity values with the relevant region of the density
space. While these values themselves cannot be interpreted spatially, shared localization of group-
specific voxel intensity profiles could be useful for hypothesis generation and motivation of further
research.
The analysis of neuroimaging data has revealed countless insights into disease processes in the
brain, yet common techniques like voxel-wise significance testing, ROI-based analysis, and network
analysis are limited by the assumption that relevant processes will occur in the same locations
across subjects. Here, we posited that the operationalization of multi-modal neuroimaging data
as subject-level multivariate densities has the potential to reveal diffuse or non-localized imaging
signatures, and proposed a method for detecting group differences locally within the density space.
We found that this method controls type I error when applied at a single point, controls the FWER
when applied over a grid, and maintains power for increasing grid sizes. The MMDT represents an
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important new tool for the exploratory analysis of neuroimaging data and other high-dimensional
subject-level data sources.
5.4. Summary
Overall, this work demonstrates the important role that statistical tools and techniques can play in
neuroimaging research. The studies herein show that ideas drawn from diverse statistical subfields
(e.g., spatial modeling, permutation inference, and high-dimensional hypothesis testing) can con-
tribute to the understanding of MS disease pathology in the brain, and complement the methods
being developed in bioengineering and computer science. Moving forward, we feel there are two
overarching future directions for this work. These directions both encompass and expand upon the
specific extensions discussed within the preceding chapters.
First, many of the proposed approaches are tailored towards cross-sectional data (i.e., one visit per
subject). Though these samples are common in research, treatment of MS within a clinical context
is characterized by repeated scans and a desire to locate and interpret changes over time. The
inclusion of longitudinal information into the proposed methods could greatly improve their utility
in patient care. Second, although these methods have been developed as discrete contributions
to MS research, there are countless unmodeled connections between them that could facilitate a
more complete account of the disease. For instance, the lesion center detection algorithm uses
only probability maps, and ignores the fact that veins provide a rich coordinate system for locating
lesion centers. Additionally, the MMDT for normal-appearing tissue does not consider the potential
links (both conceptual and physical) between lesion tissue and normal-appearing tissue that may
further explain the observed processes.
We look forward to working towards these advances, and hope that this line of research can con-




A.1. MMDT R package
The ‘mmdt’ package is an R package for conducting the multi-modal density test, as described
in Chapter 4, and based on the paper ”A local group differences test for subject-level multivariate
density neuroimaging outcomes” by Dworkin et al. published in Biostatistics. This package creates
data structures necessary for applying the method to imaging data, then allows the user to perform
the analyses, summarize the results, and create figures for visualization.
A.1.1. Installation
To get the latest development version from GitHub:
devtools :: install_github(’jdwor/mmdt’)
A.1.2. Functions
Below is a list of the functions and a description of options available to utilize through the ‘mmdt’
package. An example of how to run the analysis from beginning to end is given below, in the
”Vignette” section.
get.mmdt.obj
This function creates an ‘mmdt object’ from vectors of nifti filenames, subject IDs, and subject group
memberships. This information is compiled into a data structure that can be entered into the ‘mmdt’
function to perform the analysis.
get.mmdt.obj(masks , modal1 , modal2 , modal3=NULL ,
modal4=NULL , modal5=NULL , modal6=NULL ,
ids , groups , parallel=TRUE , cores=2, pb=TRUE)
Arguments
• masks A vector of class ‘character’ that gives .nii or .nii.gz filenames for subjects’ masks.
58
Masks demarcate which voxels should be included in the analysis, and are coded by TRUE/-
FALSE or 1/0.
• modal# Vectors of class ‘character’ that give .nii or .nii.gz filenames for a given imaging
modality across subjects. At least two modalities (modal1 and modal2) must be entered. Up
to 6 can be included.
• ids A vector of subject ids. Must be the same length as the filenames in the ‘modal#’ vectors.
• groups A vector of group membership. Must be two categories, and should be the same
length as ‘ids’.
• parallel A logical value that indicates whether the user’s computer should run the code in
parallel.
• cores If parallel = TRUE, cores is an integer value that indicates how many cores the function
should be run on.
• pb A logical value that indicates whether or not a progress bar will be shown during analysis.
mmdt
This function runs the multi-modal density test (mmdt) using an mmdt object obtained from the
‘get.mmdt.obj’ function.
mmdt(mmdt.obj , mins=NULL , maxs=NULL ,
gridsize=NULL , H=NULL , mc.adjust="BH",
nperm =500, parallel=TRUE , cores=2, pb=TRUE)
Arguments
• mmdt.obj An mmdt object obtained using the ‘get.mmdt.obj’ function.
• mins A vector giving the lower intensity bounds for each modality. If NULL, lower bounds will
be set to the minimum observed value for each modality.
• maxs A vector giving the upper intensity bounds for each modality. If NULL, upper bounds
will be set to the maximum observed value for each modality.
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• gridsize A vector giving the number of points along each dimension at which the densities
should be evaluated and tested. If NULL, this value defaults to 151x151 for two modalities,
51x51x51 for three, and 21x21x21x21 for four. Must be specified manually when analyzing
4-6 modalities.
• H The bandwidth matrix used for kernel density estimation. If NULL, a plug-in bandwidth
estimator is used.
• mc.adjust A character vector giving the multiple comparison adjustments to use. Default is
“BH”, which controls FDR using the Benjamini-Hochberg procedure. The additional options
are: ”BY”, which controls FDR using the Benjamini-Yekutieli procedure, “maxt”, which controls
FWER using max-t correction, and “tfce”, which controls FWER using threshold-free cluster
enhancement. Both of the latter options use permutation to determine significance.
• nperm If mc.adjust contains either ‘maxt’ or ‘tfce’, this is an integer value that gives the num-
ber of permutations desired to estimate the null distribution.
• parallel A logical value that indicates whether the user’s computer should run the code in
parallel.
• cores If parallel = TRUE, cores is an integer value that indicates how many cores the function
should be run on.
• pb A logical value that indicates whether or not a progress bar will be shown during analysis.
summarize.mmdt
This function outputs a summary of the mmdt output, printing whether or not there were signifi-
cant differences after adjustment for multiple comparisons, and giving the approximate locations of
differences within the density space.
summarize.mmdt(mmdt.results)
Arguments
• mmdt.results An object resulting from the ‘mmdt’ command.
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fig.mmdt





• mmdt.results An object resulting from the ‘mmdt’ command.
• type Type of image to be produced. Can be “t-statistic” or “significance”. Default is “signifi-
cance”.
• mc.adjust If type=“significance”, this states which adjustment method to use for visualization.
• coords If more than two modalities were used to create ‘mmdt.results’ object, this gives a
vector of length d [e.g., c(NA, NA, 3.25) for d=3] giving the coordinates at which the plane
should be visualized. Entries should be “NA” for the two modalities to be plotted along the x
and y axes, and other entries should give the value along the each other dimensions at which
the results should be visualized.
mmdt.to.brain
This function maps mmdt results back onto subjects’ brain image domains for visualization and
exploration purposes.
mmdt.to.brain(mmdt.results , type="t-statistic", mc.adjust="BH",
mask , modal1 , modal2 , modal3=NULL , modal4=NULL ,
modal5=NULL , modal6=NULL)
Arguments
• mmdt.results An object resulting from the ‘mmdt’ command.
• type Type of image to be produced. Can be “t-statistic” or “significance”. Default is “signifi-
cance”.
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• mc.adjust If type=“significance”, this states which adjustment method to use to determine
significance.
• mask A string that gives a .nii or .nii.gz filename for the given subject’s mask. Masks will
demarcate which voxels will be included, should be coded by TRUE/FALSE or 1/0, and should
be the same as the masks used to conduct the mmdt analyses.
• modal# Strings that give a .nii or .nii.gz filename for a subject’s given imaging modality. At
least two modalities (modal1 and modal2) must be entered. Up to 6 can be included. The
same modalities used in the mmdt analyses should be entered here, in the same order.
A.1.3. Vignette
The following gives a simple example of how the functions provided in this package should be used
to conduct and summarize the multi-modal density test.
First, an data object should be created using the ‘mmdt.obj’ function. In this example, we have four
subjects, with IDs from 1 to 4. The first two subjects are in group 1, and the last two subjects are in
group 2. We can create the mmdt.obj object as follows:
masks = c("mask01.nii", "mask02.nii", "mask03.nii", "mask04.nii")
t1s = c("t101.nii", "t102.nii", "t103.nii", "t104.nii")
flairs = c("flair01.nii", "flair02.nii", "flair03.nii", "flair04.nii")
ids = c(1, 2, 3, 4)
groups = c(1, 1, 2, 2)
mmdt.obj = get.mmdt.obj(masks = masks , modal1 = t1s , modal2 = flairs ,
ids = ids , groups = groups)
Once we have the mmdt.obj object, we can carry out the analysis using the ‘mmdt’ function. Here,
we will use the defaults for several values, and will therefore not enter them in the function call. We
will use the defaults for 1) ‘mins’ and ‘maxs’, which will perform the test over the full space of voxel
intensity values, 2) ‘gridsize’, which uses the a 151x151 grid for two modalities, and 3) the KDE
bandwidth ‘H’, which uses a plug-in estimator for each subject.
For the values that we will enter manually, we will correct for multiple comparisons using both
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Benjamini-Hochberg (for FDR control), and max-t correction with 500 permutations (for FWER con-
trol). We will also run the function in parallel, on four cores, with a progress bar.
mmdt.results = mmdt(mmdt.obj , mc.adjust = c("BH", "maxt"), nperm = 500,
parallel = TRUE , cores = 4, pb = TRUE)
Once we have the ‘mmdt.results’ object in hand, we can summarize the results using the ‘summa-
rize.mmdt’ function. Here, we simply call the function with the ‘mmdt.results’ object, and it prints
our results to the console.
summarize.mmdt(mmdt.results)
We can then create vizualization of these results using the ‘fig.mmdt’ function. We will first visual-
ize the t-statistic map, and then the significance map with Benjamini-Hochberg correction. Since
we only used two modalities (T1 and FLAIR), we do not need to enter anything for the ‘coords’
parameter.
tfig = fig.mmdt(results , type = "t-statistic")
tfig
sfig = fig.mmdt(results , type = "significance", mc.adjust = "BH")
sfig
Finally, if we want to manually check where the relevant voxel intensity profiles tend to be located in
the brain, we can use the ‘mmdt.to.brain’ function to map the t-statistics or significance values back
onto the subjects’ brain masks used to run the analysis. We would do this one at a time for each
subject, and the example below shows how we would do this for Subject 1. First, we will create
a nifti image in which voxels are assigned the t-statistic of their location in the density space, and
then we will create a nifti image in which voxels are labeled if they are located at a region of the
density space in which there was a significant group difference.
tstat.mask.s1 = mmdt.to.brain(mmdt.results , type = "t-statistic",
mask = "mask01.nii", modal1 = "t101.nii",
modal2 = "flair01.nii")
writeNifti(tstat.mask.s1 , file="mmdt.tstat .01. nii.gz")
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sig.mask.s1 = mmdt.to.brain(mmdt.results , type = "significance",
mask = "mask01.nii", modal1 = "t101.nii",
modal2 = "flair01.nii")
writeNifti(sig.mask.s1, file="mmdt.sig .01. nii.gz")
The full software package, including the complete R code underlying the functions described above,
can be accessed at github.com/jdwor/mmdt.
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